With 1000+ market research reportsand 1 billion+ data points, Future Market Insights (FMI) serves each and everyrequirement of the clients operating in the global healthcare, pharmaceuticals,and medical device industries. FMI deploys digital intelligence solutions to offercompellinginsights to report buyersthat help them in overcoming market challenges,especially at the time of a crisis. Our dedicated team of professionals performsan extensive survey for gathering accurate information associated with themarket.

FMI, in its upcoming business report, elaborates the historicaland current scenario of the global Point-Of-CareGenetic Testing market in terms of production, consumption, volume, and value.The report scrutinizes the market into various segments, regions and players onthe basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Point-Of-CareGenetic Testing market report will arm both existing and emerging marketplayers with necessary insights to craft long-term strategies as well asmaintain business continuity during a crisis such as the ongoing COVID-19pandemic.

COVID-19Impact Analysis on Point-Of-Care Genetic Testing Market

The recent outbreak of the COVID-19 has turned the spotlighton the healthcare industry, and subsequently impacted the Point-Of-Care GeneticTesting market. Severe shortages of critical medical supplies and a rapid risein number of COVID-19 cases have resulted into a revolution rather thanevolution in the healthcare ecosystems. Consequently, the impact is noticeablein the Point-Of-Care Genetic Testing market.

Following governments measures, particularly socialdistancing norms and stay-at-home orders, doctors are delaying or postponingelective surgeries unless critical to prevent the spread of the virus toindividuals with comorbidities or chronic conditions. Additionally, movementrestrictions and supply chain disruptions have created a logistical nightmarefor market players, leading to severe product shortages in the globalmarketplace.

The FMIs report includes an interesting chapter onpreliminary impact of the COVID-19 on the Point-Of-Care Genetic Testing market.This allows both leading and emerging market players to understand the marketscenario during a crisis and aids them in making sound decisions to gain adistinct competitive edge.

To Get theSample Copy of Report visit @

https://www.futuremarketinsights.com/reports/sample/rep-gb-3138

Why ChooseFuture Market Insights

Discounted prices for new customers! Offer expires soon!

Point-Of-CareGenetic Testing Market: Segmentation

Valuable information covered in the FMIs Point-Of-CareGenetic Testing market report has been segregated into key segments andsub-segments.

By Product type

By End use

Point-Of-Care Genetic Testing Market:Competition Analysis

The FMIs study presents a comprehensive analysis of global,regional, and country-level players active in the Point-Of-Care Genetic Testingmarket.Competitive information detailed in the Point-Of-Care Genetic Testingmarket report has been based on innovative product launches, distributionchannels, local networks, industrial penetration, production methods, andrevenue generation of each market player. Furthermore, growth strategies andmergers & acquisitions (M&A) activities associated with the players areenclosed in the Point-Of-Care Genetic Testing market report.

Key players covered in the report include:

Request to View TOC@

https://www.futuremarketinsights.com/toc/rep-gb-3138

ImportantQuestions Answered in the Point-Of-Care Genetic Testing Market Report

KeyOfferings of the Report

About Us

FutureMarket Insights (FMI) is a leading provider of market intelligence andconsulting services, serving clients in over 150 countries. FMI is headquartersin London, the global financial capital, and has delivery centers in the US andIndia.FMIs latest market research reports and industry analysis help businesses navigate challengesand make critical decision with confidence and clarity amidst breakneck competition.Our customize and syndicate market research reports deliver actionable insightsthat drive sustainable growth. A team of expert-led analysts at FMIcontinuously tracks emerging trends and events in a broad range of industriesto ensure that our client prepare for the evolving needs of their customer

Contact Us

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No:JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For MediaEnquiries: press@futuremarketinsights.com

Go here to see the original:
Point-of-Care Genetic Testing Market is Set to Experience Revolutionary Growth by 2027 - PharmiWeb.com

Recommendation and review posted by Bethany Smith

Michael J. Pishvaian, MD, PhD, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.

Michael J. Pishvaian, MD, PhD, associate professor, School of Medicine, and director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, Johns Hopkins Kimmel Cancer Center, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.

Pishvaian says the most important takeaway is to test patients, and this is supported by both scientific evidence as well as national recommendations. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend hemline testing for pathogenic hereditary mutations in 100% of pancreatic cancers, irrespective of their disease stage or other characteristics.

In 2019, the NCCN updated their recommendations to introduce somatic testing for patients with advanced pancreatic cancer. This accounts for roughly 80% of pancreatic cancers, says Pishvaian, and these patients, for whom there may be a novel therapy that may provide some degree of benefit, should undergo somatic testing to detect any potential actionable biomarkers.

Link:
Genetic Testing Should Be Considered for All Patients With Pancreatic Cancer - Targeted Oncology

Recommendation and review posted by Bethany Smith

UPDATE: On September 25, 2020, Governor Gavin Newsom vetoed the California Genetic Information Privacy Act (GIPA). Click here for an update.

On August 31, 2020, the California Legislature passed the Genetic Information Privacy Act (GIPA), which regulates the privacy and security aspects of Direct-to-Consumer (DTC) genetic testing and testing companies. If Governor Gavin Newsom signs GIPA into law, it will take effect on January 1, 2021.

A DTC genetic test provides consumers access to their genetic information in a variety of formats without necessarily involving their healthcare providers. The most notable examples of DTC genetic testing companies include 23andMe, Family Tree DNA, and Ancestry.com. A number of DTC genetic testing companies also provide other tailored genetic tests for a diverse range of purposes. Some of these purposes include identifying consumers genetic ancestry, food sensitivities, and predisposition for harmful diseases. Undoubtedly, DTC genetic testing has beneficial applications, but DTC genetic testing also presents data privacy and security risks if left unregulated.

Federal law already regulates genetic tests for safety through the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and the Federal Trade Commission. The Genetic Information Nondiscrimination Act also prevents discrimination in hiring or medical care based on a persons genetic proclivities. These laws, however, do not comprehensively regulate the privacy and security concerns of DTC genetic testing, which GIPA aims to address.

GIPA applies to companies that sell, market, interpret, or otherwise offer DTC genetic testing products or services and to companies that analyze genetic data obtained from consumers. GIPA, however, exempts licensed medical providers who are actively diagnosing or treating a patients medical condition.

From a security perspective, GIPA requires DTC genetic testing companies to [i]mplement and maintain reasonable security procedures and practices to protect a consumers genetic data against unauthorized access, destruction, use, modification, or disclosure. Like other data privacy and security laws, GIPA does not specifically state what constitutes reasonable security, and leaves it to individual companies to determine what is reasonable for them based on the industrys best practices.

On the privacy side, GIPA is much more detailed. GIPA requires DTC genetic testing companies to provide notice to consumers regarding their data handling and privacy practices. DTC genetic testing companies must also obtain consumers express consent for collection, use, and disclosure of their genetic data and separate express consent for each use and disclosure of their genetic data. Further, GIPA requires companies to enable users to access and delete their genetic data, and to comply with a consumers request to destroy any genetic samples, subject to some federal provisions for regulatory compliance, within thirty days of the request.

In sum, DTC genetic testing companies should assess gaps in their data privacy and security procedures, and ensure compliance with GIPA. Failure to comply with this law carries stiff penaltiesup to $1,000 penalty for each negligent violation, and intentional violations ranging from $1,000 to $10,000 per incident. If these penalties are aggregated in a class action lawsuit, companies could face significant liability for GIPA violations.

Editor: Arsen Kourinian

See the original post here:
California Passes the Genetic Information Privacy Act | Knobbe Martens - JD Supra

Recommendation and review posted by Bethany Smith

(WXYZ) When Nate Hahn decided to visit his family in Illinois this past July he thought getting a COVID-19 test before would be a smart and safe move.

The 35-year-old went to a metro-Detroit clinic a week before traveling. While the test site indicated that he should get his results within three days enough time to figure out his status before the trip it ended up taking six.

"I didnt get my results by the time I left," said Hahn, "So it sort of defeated the purpose."

The scenario has played out hundreds of times across the state. Even the most fastidious of planners struggle when it comes to timing out a COVID-19 test. But what's causing the delays and uncertainty? According to medical experts, the moving-target comes down to the labs that are being used.

"The more capacity a given lab has, the more samples get sent to that given lab and it overwhelms the lab," said Dr. Phil Levy, who runs a COVID-19 testing site through Wayne Health.

In Michigan, there are over 400 COVID-19 test sites created by medical providers (hospitals, urgent cares, primary cares, pharmacies), as well as some local health departments or local governments. Each site can then contract with a lab of their choosing to process the tests.

These labs, according to Levy, play a major roll in the test-turn around time especially when they're non-local and fielding requests from regions across the country. He uses Wisconsin which is currently seeing a spike in COVID-19 cases as an example.

"Wisconsin all of a sudden its a hotbed," he said, "that then has a collateral impact on all the other locations that are sending tests to those labs as well."

According to Levy many municipalities at the start of the pandemic decided to contract with large, national labs to ensure their tests were processed. But as COVID-19 levels increase in other regions and more people get tested local wait times can get pushed back as well, even if numbers are dwindling in the state.

This scenario played out in the City of Detroit who in March signed a $1.4 million contract with New Jersey-based Bio Reference to help process COVID-19 tests at the State Fairgrounds.

"When we went to Bio Reference there was no one in Michigan that had it and could do it, the testing kits were not there. Thats how we established the relationship," said Hakim Berry, City of Detroit Chief Operating Officer, who helped set up the State Fairgrounds site as a way to help alleviate some of the pressure local hospitals were facing to get testing done.

"During the height of the pandemic, we were shipping out twice a day to New Jersey, sending the samples on dry ice. We were doing up to 1200 a day at its height," Berry continued, adding that at the time results were coming back in three to four days.

But as Michigan's COVID-19 cases began to dip the wait times for COVID-19 tests at the State Fairgrounds began to increase.

"As our numbers went down, everywhere else in the country went up, so thats when our test results started taking seven days, because they were getting slammed by other hot areas," said Berry, who explained that at this point the city began looking for local labs to help ensure that testing at nursing homes could continue without new lag times.

"We had a concern about senior care facilities, senior home apartment complexes and the like, adult foster care and we didn't have enough of the Abbott Rapid Tests at that time," said Berry, explaining that at that time the city began working with Jackson, MI based Garcia Lab.

"It really helped us to address and control the spread among the senior population," said Berry.

This use of local labs is, according to Levy, a key-factor in testing turnaround.

"Everybody looked to the big lab companies first, figured thats just the simplest way to do it. They became overwhelmed and there wasnt the ready accessibility of these smaller labs to run the tests," he said, explaining that he also initially was using a national lab Quest for his testing of frontline workers at the start of the pandemic, but soon had to look for other solutions.

"We were getting two to three day turn around times initially, that gradually became seven to nine-day turn around times," he said. "We started to look for other lab sources."

Today he works with a number of local labs. But finding them wasn't easy.

"The relationships that weve developed with labs have come either through someone who knows somebody or somebody who knows were in the testing business so to say and has reached out to us," said Levy, explaining that it's still very much a word-of-mouth system.

"Some of it is a lack of familiarity and some of it is just a lack of understanding of the business," he continued.

One lab he works with is NxGen in Grand Rapids.

Prior to COVID-19 the lab focused on genetic testing, working with OBGYNs across the country. They made the transition to COVID-19 tests in the winter when they saw the pandemic coming closer to home. But even as they made the shift, they still say they're not operating at full capacity.

"We started reaching out to I call them the three Fs: friends, family, and fools and asking them for help and connecting us with the right people," said CEO Alan Mack, explaining that while NxGen could process 9,000 tests daily, it is only processing only about 2,500 tests.

"We didnt have some magical Rolodex that put us in touch with all the hospitals and all the other laboratories," he said, explaining that in May he actually reached out to some of the bigger, national testing companies to see if he could take on some of their cases to help reduce times.

"We reached out to a couple of them to say, 'hey we have unused capacity, wed love to be able to help you out'" he said, explaining the response was a resounding no.

"They told us to go pound sand and they dont need our help, he said, adding: "At the same time there are a lot of patients waiting two weeks for their results."

While big testing labs being inundated with tests from other states can play a role in test turnaround time, Mack contends there are other factors at play. He points to supply scarcity still impacting test-turn around.

In September, for example, Henry Ford Health System told the state that while they had the capacity to turn around 1,500 tests a day. Supply constraints, however, reduced that number to only 670 tests. They were still, however, running 1,400 tests daily.

When hospital labs are overwhelmed, according to Mack, they can send out tests to outside labs. The NxGen CEO, however, said this doesn't always happen.

"It amounts to about $24 per sample loss when they send these samples out," he said, pointing to the fact that Michigan is a "no mark up" state, which means hospitals must charge what a lab charges, even if they lose money sending a sample out.

"If theyre having to send thousands of these per day well," he continued, "that adds up very quickly and it becomes a significant financial issue for that institution."

According to the Michigan Department of Health and Human Services, the current turnaround time for a COVID-19 test is two to three days. But this statement comes with an important caveat: "turnaround time varies by laboratory."

View post:
Wait times to get COVID test results can vary here's why - WXYZ

Recommendation and review posted by Bethany Smith

Sponsored Content by the Janssen Pharmaceutical Companies of Johnson & Johnson

When it comes to new therapies, patients with lung cancer face a significant global unmet medical need. Not only does lung cancer have the highest mortality rate of all cancers worldwide, its associated with significant heterogeneity with many driver mechanisms that make it complex and difficult to treat.

The driver mechanisms we have come to understand have provided important insights into new approaches for treating lung cancer, said Matt Lorenzi, PhD., Vice President, Disease Area Leader, Solid Tumor Targeted Therapy, Janssen. Through deeper knowledge about the biology of lung cancer, we are making progress in the advancement of precision medicines that target specific pathways, including patients who have developed a resistance to other therapies.

Ongoing research efforts are continuing to show promise. Targeted therapy approaches that have derived from an understanding of driver mechanisms have helped contribute to a decline in mortality from non-small cell lung cancer (NSCLC), the most common type of lung cancer, as recently reported in The New England Journal of Medicine. In addition, immunotherapy-based approaches to reactivate or redirect a patients immune system for tumor targeting are standard of care or showing future promise, respectively.

For key oncogenic driver pathways, researchers are learning much more about the role that various genetic mutations and alterations play, and development efforts are focused on precisely targeting these defects. One of the most common genetic alterations in NSCLC is epidermal growth factor receptor (EGFR), a mutation that helps cells grow and divide. While targeting EGFR has proven to be an effective treatment intervention, tumors eventually become resistant to treatment. Therefore, the role of bispecific therapies, meaning treatments that target more than one pathway, is becoming increasingly important in the treatment of lung and other types of cancer, along with new combination-based regimens.

As researchers learn more about non-small cell lung cancer specifically as it relates to how certain genetic factors can influence the severity of disease and how a patient responds to treatment the importance of genetic testing is becoming clear, as is the importance of novel modalities and combination therapies, said Lorenzi. The complexity of lung cancer highlights the importance of developing regimens that incorporate multiple mechanisms of action to target the key pathways underlying the disease. We aim for treatment to act against each persons unique cancer, as effectively and safely as possible.

While targeted therapies are among the most discussed current research avenues, other areas are proving promising as well. One uses an approach called synthetic lethality against additional genetic alterations in lung cancer, and another uses immune cell re-direction to leverage the immune system to specifically target lung cancer cells with tumor-associated antigens.

These therapeutic developments offer a promising outlook for the future of lung cancer treatment and are further complemented by exciting efforts underway through the Johnson & Johnson Lung Cancer Initiative, which are focused on unique approaches to intercept the disease at its earliest stage or to prevent it altogether.

Despite many encouraging treatment advances in lung cancer, its five-year survival rate remains among the lowest of any cancer. Improving this statistic will require the ongoing development of novel treatments, the identification of strategic collaborators, and the advancement of scientific leadership in disease prevention and interception. As an organization that has been at the forefront of the discovery and development of new cancer therapies for more than a decade, Janssen, together with the Johnson & Johnson Lung Cancer Initiative, is committed to advancing novel approaches to support efforts throughout the medical community to transform the trajectory of lung cancer.

Read the original post:
Addressing Unmet Medical Needs of Patients with Lung Cancer - Cancer Therapy Advisor

Recommendation and review posted by Bethany Smith

Overview for Direct-to-consumer Genetic Testing Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Direct-to-consumer Genetic Testing market focuses on encompassing major statistical evidence for the Direct-to-consumer Genetic Testing industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Direct-to-consumer Genetic Testing study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Direct-to-consumer Genetic Testing industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Direct-to-consumer Genetic Testing market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Direct-to-consumer Genetic Testing report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Direct-to-consumer Genetic Testing market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Direct-to-consumer Genetic Testing Market report @https://www.arcognizance.com/enquiry-sample/1370303

Key players in the global Direct-to-consumer Genetic Testing market covered in Chapter 4:Myriad Genetics, Inc.23andMe, Inc.InvitaeAmbry GeneticsLaboratory Corporation of AmericaAfrican AncestryMyHeritageAncestrybyDNACounsyl, Inc.Pathway GenomicsDNA Services of AmericaPositive Bioscience Ltd.Quest DiagnosticsSonora Quest LaboratoriesGene by GeneMapmygenome

In Chapter 11 and 13.3, on the basis of types, the Direct-to-consumer Genetic Testing market from 2015 to 2026 is primarily split into:Diagnostic screeningPrenatal, newborn screening, and pre-implantation diagnosisRelationship testing

In Chapter 12 and 13.4, on the basis of applications, the Direct-to-consumer Genetic Testing market from 2015 to 2026 covers:HealthNutritionFitness

Brief about Direct-to-consumer Genetic Testing Market Report with [emailprotected]https://www.arcognizance.com/report/global-direct-to-consumer-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

Get 20% complementary customization along with purchase of Direct-to-consumer Genetic Testing Industry [emailprotected]https://www.arcognizance.com/purchase/1370303

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Direct-to-consumer Genetic Testing Market

Chapter Four: Players Profiles

Chapter Five: Global Direct-to-consumer Genetic Testing Market Analysis by Regions

Chapter Six: North America Direct-to-consumer Genetic Testing Market Analysis by Countries

Chapter Seven: Europe Direct-to-consumer Genetic Testing Market Analysis by Countries

Chapter Eight: Asia-Pacific Direct-to-consumer Genetic Testing Market Analysis by Countries

Chapter Nine: Middle East and Africa Direct-to-consumer Genetic Testing Market Analysis by Countries

Chapter Ten: South America Direct-to-consumer Genetic Testing Market Analysis by Countries

Chapter Eleven: Global Direct-to-consumer Genetic Testing Market Segment by Types

Chapter Twelve: Global Direct-to-consumer Genetic Testing Market Segment by Applications12.1 Global Direct-to-consumer Genetic Testing Sales, Revenue and Market Share by Applications (2015-2020)

12.1.1 Global Direct-to-consumer Genetic Testing Sales and Market Share by Applications (2015-2020)

12.1.2 Global Direct-to-consumer Genetic Testing Revenue and Market Share by Applications (2015-2020)

12.2 Health Sales, Revenue and Growth Rate (2015-2020)

12.3 Nutrition Sales, Revenue and Growth Rate (2015-2020)

12.4 Fitness Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Direct-to-consumer Genetic Testing Market Forecast by Regions (2020-2026) continue

List of tablesList of Tables and FiguresTable Global Direct-to-consumer Genetic Testing Market Size Growth Rate by Type (2020-2026)Figure Global Direct-to-consumer Genetic Testing Market Share by Type in 2019 & 2026Figure Diagnostic screening FeaturesFigure Prenatal, newborn screening, and pre-implantation diagnosis FeaturesFigure Relationship testing FeaturesTable Global Direct-to-consumer Genetic Testing Market Size Growth by Application (2020-2026)Figure Global Direct-to-consumer Genetic Testing Market Share by Application in 2019 & 2026Figure Health DescriptionFigure Nutrition DescriptionFigure Fitness DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Direct-to-consumer Genetic Testing Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Direct-to-consumer Genetic Testing Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Direct-to-consumer Genetic TestingFigure Production Process of Direct-to-consumer Genetic TestingFigure Manufacturing Cost Structure of Direct-to-consumer Genetic TestingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Myriad Genetics, Inc. ProfileTable Myriad Genetics, Inc. Production, Value, Price, Gross Margin 2015-2020Table 23andMe, Inc. ProfileTable 23andMe, Inc. Production, Value, Price, Gross Margin 2015-2020Table Invitae ProfileTable Invitae Production, Value, Price, Gross Margin 2015-2020Table Ambry Genetics ProfileTable Ambry Genetics Production, Value, Price, Gross Margin 2015-2020Table Laboratory Corporation of America ProfileTable Laboratory Corporation of America Production, Value, Price, Gross Margin 2015-2020Table African Ancestry ProfileTable African Ancestry Production, Value, Price, Gross Margin 2015-2020Table MyHeritage ProfileTable MyHeritage Production, Value, Price, Gross Margin 2015-2020Table AncestrybyDNA ProfileTable AncestrybyDNA Production, Value, Price, Gross Margin 2015-2020Table Counsyl, Inc. ProfileTable Counsyl, Inc. Production, Value, Price, Gross Margin 2015-2020Table Pathway Genomics ProfileTable Pathway Genomics Production, Value, Price, Gross Margin 2015-2020Table DNA Services of America ProfileTable DNA Services of America Production, Value, Price, Gross Margin 2015-2020Table Positive Bioscience Ltd. ProfileTable Positive Bioscience Ltd. Production, Value, Price, Gross Margin 2015-2020Table Quest Diagnostics ProfileTable Quest Diagnostics Production, Value, Price, Gross Margin 2015-2020Table Sonora Quest Laboratories ProfileTable Sonora Quest Laboratories Production, Value, Price, Gross Margin 2015-2020Table Gene by Gene ProfileTable Gene by Gene Production, Value, Price, Gross Margin 2015-2020Table Mapmygenome ProfileTable Mapmygenome Production, Value, Price, Gross Margin 2015-2020Figure Global Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Global Direct-to-consumer Genetic Testing Revenue ($) and Growth (2015-2020)Table Global Direct-to-consumer Genetic Testing Sales by Regions (2015-2020)Table Global Direct-to-consumer Genetic Testing Sales Market Share by Regions (2015-2020)Table Global Direct-to-consumer Genetic Testing Revenue ($) by Regions (2015-2020)Table Global Direct-to-consumer Genetic Testing Revenue Market Share by Regions (2015-2020)Table Global Direct-to-consumer Genetic Testing Revenue Market Share by Regions in 2015Table Global Direct-to-consumer Genetic Testing Revenue Market Share by Regions in 2019Figure North America Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Europe Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Asia-Pacific Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Middle East and Africa Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure South America Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure North America Direct-to-consumer Genetic Testing Revenue ($) and Growth (2015-2020)Table North America Direct-to-consumer Genetic Testing Sales by Countries (2015-2020)Table North America Direct-to-consumer Genetic Testing Sales Market Share by Countries (2015-2020)Figure North America Direct-to-consumer Genetic Testing Sales Market Share by Countries in 2015Figure North America Direct-to-consumer Genetic Testing Sales Market Share by Countries in 2019Table North America Direct-to-consumer Genetic Testing Revenue ($) by Countries (2015-2020)Table North America Direct-to-consumer Genetic Testing Revenue Market Share by Countries (2015-2020)Figure North America Direct-to-consumer Genetic Testing Revenue Market Share by Countries in 2015Figure North America Direct-to-consumer Genetic Testing Revenue Market Share by Countries in 2019Figure United States Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Canada Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Mexico Direct-to-consumer Genetic Testing Sales and Growth (2015-2020)Figure Europe Direct-to-consumer Genetic Testing Revenue ($) Growth (2015-2020)Table Europe Direct-to-consumer Genetic Testing Sales by Countries (2015-2020)Table Europe Direct-to-consumer Genetic Testing Sales Market Share by Countries (2015-2020)Figure Europe Direct-to-consumer Genetic Testing Sales Market Share by Countries in 2015Figure Europe Direct-to-consumer Genetic Testing Sales Market Share by Countries in 2019Table Europe Direct-to-consumer Genetic Testing Revenue ($) by Countries (2015-2020)Table Europe Direct-to-consumer Genetic Testing Revenue Market Share by Countries (2015-2020)Figure Europe Direct-to-consumer Genetic Testing Revenue Market Share by Countries in 2015Figure Europe Direct-to-consumer Genetic Testing Revenue Market Share by Countries in 2019Figure Germany Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure UK Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure France Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Italy Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Spain Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Russia Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Asia-Pacific Direct-to-consumer Genetic Testing Revenue ($) and Growth (2015-2020)Table Asia-Pacific Direct-to-consumer Genetic Testing Sales by Countries (2015-2020)Table Asia-Pacific Direct-to-consumer Genetic Testing Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Direct-to-consumer Genetic Testing Sales Market Share by Countries in 2015Figure Asia-Pacific Direct-to-consumer Genetic Testing Sales Market Share by Countries in 2019Table Asia-Pacific Direct-to-consumer Genetic Testing Revenue ($) by Countries (2015-2020)Table Asia-Pacific Direct-to-consumer Genetic Testing Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Direct-to-consumer Genetic Testing Revenue Market Share by Countries in 2015Figure Asia-Pacific Direct-to-consumer Genetic Testing Revenue Market Share by Countries in 2019Figure China Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Japan Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure South Korea Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Australia Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure India Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Southeast Asia Direct-to-consumer Genetic Testing Sales and Growth Rate (2015-2020)Figure Middle East and Africa Direct-to-consumer Genetic Testing Revenue ($) and Growth (2015-2020)continue

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

Go here to read the rest:
Direct-to-consumer Genetic Testing Market Size 2020, Share, Global Industry Analysis and Competitive Landscape (Effect of the COVID-19 Pandemic) -...

Recommendation and review posted by Bethany Smith

Alex Peters is Dazed Beautys news writer. She picked up the phrase Its all happening from Almost Famous as a teen and it now exclusively makes up her vocabulary. Although in theory she likes the idea of a queer mullet, she is currently rocking the latest lockdown trend: Kajillionaire hair. Here, she shares her choice for Product of the Week a weekly round-up of the Dazed Beauty team and wider communitys must-have buys.

Brand: Augustinus Bader

Product: The Cream

Price: 205

As head of stem cell research at the University of Leipzig, Professor Augustinus Bader spent 30 years working with burns victims, developing a groundbreaking gel in 2008 that could heal third-degree burns without the need for skin grafts. Its this revolutionary stem cell technology the patented Trigger Factor Complex (TFC8) which lies at the heart of his skincare label and its hero product The Cream.

Powered by this technology, with consistent use (the Cream asks that you remain devoted to it for 27 days, using nothing else), the products activate and orchestrate the body's innate regenerative processes which basically means that when you use them your skin cells repair themselves. This helps with reducing the signs of ageing and environmental damage, reducing scarring and redness, and improving tone and texture.

Thats all very scientific, but the most important question is does it actually work? And for me it does. My skin is on the oily side as well as being sensitive and acne-prone so I use the Cream, rather than the Rich Cream which is better suited to dry skin types. The cream itself has a light texture that absorbs quickly and doesnt feel sticky. Two pumps is enough to cover your face and it goes on very smoothly. It has quite a distinctive scent, so if you are nose-sensitive be prepared. Its hard to describe clinical rather than artificial. It comes in a weighty blue and copper tube that feels fancy when youre using it.

I am not always great at using it consistently, particularly since we test out so many products as part of our job, but I have found that when I do, my skin looks noticeably better. My tone is more even and less red, the texture is better, scars look more faded, and I would tentatively say that it seems like I get fewer spots.

I would like to say, however, that the product is definitely on the higher end of the spectrum price-wise, and if you cannot afford it, please do not worry. There are a lot of great options out there that are more affordable and also very effective. If this is something that you can afford, I would highly recommend.

If I were communicating to an alien only using hand gestures, I would describe it with... Just a solid thumbs up. Or through elaborately miming the process of cell renewal.

It sounds like... A reassuring older German professor telling you efferyzing vill be alright and in the background the sound of a fire crackling.

If it was a meme it would be... Sorry to this man. Totally unrelated but its my favourite meme.

The fictional character who would use it is... Bette Porter from The L Word.

Alex Peters's Product of the Week

Go here to read the rest:
The luxury skincare splurge that will help repair your skin cells - Dazed

Recommendation and review posted by Bethany Smith

CRANFORD, N.J., Oct. 7, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ("Novellus") to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies.

NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ("NC-iMSCs") to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Several cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the emergency authorization program.

NC-iMSCs are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges (e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). iMSCs overcome these challenges because they:

Globally, there are 3 million cases of ARDS every year out of which approximately 200,000 cases are in the United States. The COVID-19 pandemic has added significantly to the number of ARDS cases. Once the COVID patients advance to ARDS, they are put on mechanical ventilators. Death rate among patients on ventilators can be as high as 50% depending on associated co-morbidities. There are no approved treatments for ARDS, and the current standard of care only attempts to provide symptomatic relief.

"NoveCite iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of the high potency seen in Novellus' pre-clinical studies, and because iMSCs are iPSC-derived, and therefore overcome the manufacturing challenges associated with donor derived cells," said Myron Holubiak, Chief Executive Officer of Citius.

"We are excited to be part of this effort because of the promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Dr. Matthew Angel, Chief Science Officer of Novellus. "Our iMSC technology has multimodal immunomodulatory mechanisms of action that make it potentially promising therapy to treat acute respiratory diseases."

About Citius Pharmaceuticals, Inc.

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Therapeutics, Limited

Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its patented non-immunogenic mRNA high specificity gene editing, mutation-free & footprint-free cell reprogramming and serum insensitive mRNA lipid delivery technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

About NoveCite iMSC (NC-iMSC)

NoveCite's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The NC-iMSCs produced from this clonal technique are differentiated from human donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, NC-iMSCs exhibit superior potency and high cell viability. NC-iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. NC-iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

First generation (human donor-derived) MSCs are isolated from donated tissue followed by "culture expansion". Since only a relatively small number of cells are isolated from each donation, first generation MSCs are increased by growing the cells in culture. Unfortunately, these type of MSCs start to lose potency, and ultimately become senescent. Each donation produces a limited number of MSCs, so a continuous supply of new donors is needed to produce commercial scale. The number and quality of MSCs that can be isolated from different donors can vary substantially.

About Acute Respiratory Distress Syndrome (ARDS)

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability. ARDS is a frequent complication of patients with COVID-19. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risks associated with developing the NoveCite technology as a treatment for ARDS; risks associated with developing any of our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development, including the NoveCite technology; our ability to obtain, perform under and maintain licensing, financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105(M) 646-522-8410ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-signs-an-exclusive-worldwide-licensing-agreement-with-novellus-therapeutics-for-unique-imsc-therapy-for-acute-inflammatory-respiratory-conditions-including-covid-19-related-acute-respiratory-distress-syndrom-301147409.html

SOURCE Citius Pharmaceuticals, Inc.

Company Codes: NASDAQ-SMALL:CTXR

More here:
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory...

Recommendation and review posted by Bethany Smith

Despite the challenges brought about by Covid-19, leading cosmetic manufacturers, including Mibelle Biochemistry, Cargill Beauty, Givaudan Active Beauty and Lucas Meyer, put forward their most creative innovations for consideration by the in-cosmetics Global Awards jury.

Judged across three categories - Best Active Ingredient, Best Functional Ingredient and Best Green Ingredient - by some of the industrys foremost experts, the awards recognise the cosmetic ingredient manufacturers who are helping to push the boundaries of innovation, while responding to evolving consumer demands.

The winners were announced yesterday during a virtual ceremony from a list of finalists dominated by skin care ingredients.

Scooping both the Gold and Silver awards in the Best Active Ingredient category, Vytrus Biotech was recognised for its Kannabia Sense and Deobiome Noni ingredients.

Kannabia Sense took the top accolade. This probiotic treatment stimulates the skin microbiota to produce an in-situ postbiotic cocktail that promotes the synthesis of cutaneous oxytocin. Recommended for use in sensitive skin treatments, anti-ageing cosmetic products and delicate facial treatments, it is made from plant stem cells of Cannabis sativa.

Deobiome Noni is a prebiotic deodorant treatment that reduces the generation of body odour while allowing the skin to breathe and respecting the skin microbiota.

Closing the category, Mibelle Biochemistry and Clariant Active were announced as this years joint Bronze Award winners.

Alpine Rose Active, Mibelle Biochemistrys novel senolytics concept, was chosen for its ability to eliminate senescent skin cells and protect skin proteins from oxidative stress.

Clariant Active was applauded for Prenylium. Thanks to Clariants Plant Milking technology, Prenylium is extracted from the root of the mulberry tree (Morus Alba) without causing any damage. This innovative and sustainable approach to sourcing helps to stimulate root growth and results in a concentration of prenylated flavonoids 2000% higher than what is typically found in mulberry root extracts.

German cosmetic manufacturer Symrise took the top award in the Best Functional Ingredient category for its Symrise SymEffect Sun. Based entirely on renewable raw materials from responsible sources, the new ingredient combines the advantages of conventional sunscreen products with the increasing sustainability requirements of consumers.

Also demonstrating a sustainable approach to sun protection, Dow Chemical was awarded the Silver award for its SunSpheres BIO SPF Booster, a bio-based and readily biodegradable SPF boost that enables greater SPF efficiency in suncare and daily skincare products.

The category also honoured two bronze award winners: Clariant and Gattefoss. The former was awarded for Velsan Flex which, thanks to its high water solubility and Renewable Carbon Index (RCI) of 93%, offers preservation boosting powers together with broad formulation flexibility. Gattefosss Emulium Dolcea MB a natural origin O/W emulsifier - has the ability to create a wider range of textures, from fluid serum to thick butter in a wide range of applications, such as skincare, suncare, make up and haircare.

As sustainability continues to drive cosmetic manufacturers to assess the ingredients used in their formulations, this years Green Ingredient Award - in partnership with Ecovia Intelligence - recognises the ingredients championing sustainability in the personal care and beauty market.

Henry Lamotte Oils Paradise Nut Oil/Magdalena River Nut Oil scooped the Gold Award for its ability to support the regeneration of the skins lipid film, while improving the water retention capability of the skin, reducing trans-epidermal water loss.

Unveiled as the Silver Award winner, Cargill Beautys FiberDesign Sensation was praised for its approach to sustainability and upcycling. Derived from 100% natural origins, the texturiser and emulsion stabiliser, designed specifically for skincare, is based on citrus peel fibres from the pectin production side stream.

Joining the line-up of award winners, Minasolve SAS scooped the Bronze Award for its A-Leen Aroma-3, a nature-derived perfuming agent that also offers a broad-spectrum antimicrobial effect. It is a 100% natural version of phenylpropanol, it is produced from cassia essential oil.

Cosmetic Ingredients - October 2020

For more information on the latest cosmetic ingredients launches, also read our special issue:

How far will clean beauty go?

Interest in upcycled ingredients expected to rise in the cosmetics industry

Driven by new consumer preferences, demand for cupuau butter is on the rise

in-cosmetics Awards 2020

Ingredient news: Akott, BASF, Berkem, Clariant, Codif, Covestro, DSM, Firmenich, Givaudaun, Grolman, Imerys, Inter Actifs, Lubrizol, Mibelle, Sederma, Seppic, Silab, Symrise

Read online for free or download the pdf version here.

More here:
Who are the winners of the in-cosmetics Global Awards 2020? - Premium beauty

Recommendation and review posted by Bethany Smith

Private equity company The Carlyle Group has taken legal advice from Latham & Watkins on its acquisit...

Private equity company The Carlyle Group has taken legal advice from Latham & Watkins on its acquisition of the Colombian operations of American hydrocarbon exploration company Occidental Petroleum, for approximately USD 825 million.

White & Case acted as Occidentals legal counsel with Bracewell advising Carlyle International Energy Partners (CIEP), which is providing equity for the transaction.

Of the entire purchase price, USD 700 million is due up front. The transaction is expected to close in the fourth quarter of 2020, subject to meeting customary closing conditions.

Colombia Onshore, which has been present in Colombia for over 40 years, holds its most significant operations in the Llanos Norte Basin in the Department of Arauca, as well as the Middle Magdalena Basin in the Department of Santander.

The former CEO of BP, Tony Hayward, who collaborates with The Carlyle Group to help drive its upstream investments in Colombia, will become the executive chairman of Colombia Onshore following the acquisition, a role to which he will bring a wealth of experience amassed over years in the sector, said head of CIEP, Marcel van Poecke, in a statement.

Hayward expressed gratitude at the prospect of returning to lead a major Colombian oil and gas business, highlighting that Colombian Onshore has a significant presence in all of Colombias principal hydrocarbon basins with a portfolio of attractive onshore investment opportunities from production to development and exploration.

Following the acquisition, The Carlyle Group intends to take on a strategic plan involving field life extension and a focus on operating efficiency, while developing Colombia Onshores environmental, social and governance (ESG) initiatives.

Hayward added that the company has an exemplary track record in ESG - one that [it] will look to continue and improve on, also stating that he is looking forward to continuing the business strategic partnership with [Frankfurt Stock Exchange-listed] Ecopetrol, formerly known as Empresa Colombiana de Petrleos.

London-based corporate partners Sam Newhouse and Simon Tysoe led Latham & Watkins advisory team, alongside New York-based partner Tony Del Pino and associates, Hector Sants, Alan Rozen, Evelyne Girio, James Thomson, Amrita Ahuja, and Pierre-Axel Aberg.

The Carlyle Group enlisted Simpson Thacher & Bartlett on raising EUR 6.4 billion for its Carlyle Europe Partners V fund, in October last year.

See more here:
Ex-BP CEO will lead The Carlyle Group's newly acquired Colombia Onshore - ICLG.com

Recommendation and review posted by Bethany Smith

Latest Oral & Dental Probiotics Market Research Report

The research report focuses on target groups of customers to help players to effectively market their products and achieve strong sales in the global Oral & Dental Probiotics market. It someone useful and relevant market information as per the business needs of players. Feature are provided with validated and authorizemarket forecast figures such as CAGR, revenue, production, consumption, and market share. Our straight market data equips players to plan powerful strategies ahead of time.

Major Key Players of the Oral & Dental Probiotics Market are: Now Foods, Hyperbiotics, Oragenics, Life Extension, Lallemand,

Get Access to Report Sample: https://garnerinsights.com/COVID-19-Impact-on-Global-Oral-&-Dental-Probiotics-Market-Size-Status-and-Forecast-2020-2026#request-sample

Major Types of Oral & Dental Probiotics covered are: Powder, Chewable tablets, Others

Major Applications of Oral & Dental Probiotics covered are: Child, Adult

The report offers deep geographical investigation where key regional and country level markets are brought to light. The vendor point of view is also analyzed in depth to reveal current and future market challenges and business tactics adopted by leading companies to tackle them.Market dynamics including drivers, restraints, challenges, opportunities, influence factors, and trends are specially focused upon to give a clear understanding of the global Oral & Dental Probiotics market.

Get Discount on this Report:https://garnerinsights.com/COVID-19-Impact-on-Global-Oral-&-Dental-Probiotics-Market-Size-Status-and-Forecast-2020-2026#discount

The research study includes in depth analysis where important type, application, and regional segments are studied in quite some detail.It also includes market channel, distribute, and customer analysis, industry cost analysis, organization profiles, market analysis by application, production, revenue, and price trend analysis by type, production and consumption analysis by region, and various other market studies.

The Oral & Dental Probioticsreport will the thorough study of the key business players to grasp their business methods, annual revenue, company profile and their contribution to the worldmarket share.The report covers a huge area of information including an industry overview, comprehensive analysis, definitions and classifications, applications, and expert opinions.

The Oral & Dental Probiotics Market report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, Asia Pacific, South America, Middle East and Africa after evaluating political, economic, social and technological factors impression the market in these regions.

The Oral & Dental Probiotics Market report wraps:

In the end , The objective of the market research report is the current status of the market and in accordance classifies it into a few object. The report takes into consideration the firstmarket players in every area from over the globe.

View Full Report Description with TOC:https://garnerinsights.com/COVID-19-Impact-on-Global-Oral-&-Dental-Probiotics-Market-Size-Status-and-Forecast-2020-2026

Visit link:
Oral & Dental Probiotics Market is projected to witness substantial growth by 2026 | Now Foods, Hyperbiotics, Oragenics, Life Extension examined...

Recommendation and review posted by Bethany Smith

Gosselies, Belgium, 5 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, Link Health Pharma Co., Ltd (Link Health) and Shenzhen Pregene Biopharma Company, Ltd (Pregene) today announce the signing of an exclusive license agreement for the manufacturing, clinical development and commercialization of Bone Therapeutics allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China (including Hong Kong and Macau), Taiwan, Singapore, South Korea, and Thailand.

Under the agreement, Bone Therapeutics is eligible to receive up to 55 million in development, regulatory and commercial milestone payments including 10 million in upfront and milestone payments anticipated in the next 24 months. Bone Therapeutics is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB. Bone Therapeutics retains development and commercialization rights to ALLOB in all other geographies outside of those covered by this agreement. As a result, Bone Therapeutics will continue to concentrate on its development and commercialization plans for ALLOB in the US and Europe and novel innovative cell-based products globally.

This collaboration between Bone Therapeutics, Link Health and Pregene expands our geographic reach and demonstrates the global commercial potential of ALLOB,said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. We already have operational experience in Asia with the Phase III clinical trial of our lead product JTA-004 in Hong Kong. We selected Link Health and Pregene to partner with us in Asia as a result of their expertise in advanced therapeutics and cell therapies, their proven track record of development and commercial implementation in Chinese and Asian markets, and Pregenes well established cell therapy manufacturing capacity. Bone Therapeutics will continue to develop the ALLOB cell therapy platform for other markets while exploring additional partnership opportunities in the U.S. and Europe.

The agreement grants Link Health and Pregene exclusive rights to clinically develop and commercialize ALLOB for the treatment of human bone disorders in Greater China, Taiwan, Singapore, South Korea, and Thailand. All rights for China will be transferred to Pregene and Link Health will gain rights for the remaining countries Bone Therapeutics will share its patented proprietary manufacturing expertise for the expansion and differentiation of bone-forming cells and has the option to sell clinical supplies to Link Health and Pregene in preparation for their clinical development of ALLOB.

This collaboration and license agreement for Bone Therapeutics ALLOB provides a strong addition to our pipeline. ALLOB has demonstrated the potential to reduce the recovery time and stimulate bone growth for a variety of bone conditions, and to have a considerable impact on patients lives,said Yan Song, PhD, Chief Executive Officer of Link Health. It is important for Link Health to collaborate with companies that have strong therapeutic product portfolios and entrepreneurial management. This partnership with Bone Therapeutics is a direct result of our shared commitment to appreciate the enormous potential of cell therapy and regenerative medicine.

Pregene now has a flourishing portfolio of CAR-T cell therapy-based cancer treatments. Bone Therapeutics ALLOB provides anallogeneic, off-the-shelf cell therapy that expands our portfolio of cell therapies to include the sizable commercial potential of orthopedics,said Hongjian Li, Co-founder and Chief Executive Officer of Pregene. We expect to be able to leverage our extensive international cell and gene therapy experience to develop Bone Therapeutics ALLOB platform and subsequently launch products in China and Southeast Asian markets.

ALLOB, an allogeneic and off-the-shelf cell therapy product manufactured through a proprietary, scalable production process, consists of human bone-forming cells derived from cultured bone marrow mesenchymal stem cells of healthy adult donors. In preclinical studies ALLOB has shown to reduce healing time in a delayed-union fracture model by half, and has demonstrated good tolerability and signs of efficacy in two Phase IIa studies for two separate indications. The Companys randomized, placebo-controlled, double-blind Phase IIb clinical trial in patients with difficult tibial fractures has received approval from regulatory authorities in six of the seven planned European countries to date, and is expected to enroll the first patient later this year.

About Link Health Pharma Co., Ltd

Link Health is a leading Chinese pharmaceutical company based in Guangzhou, Southern China, focusing on the development of innovative drugs for unmet medical needs.

Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently. The company has a drug development pipeline of 5 clinical stage assets and 1 under NDA reviewing in China.

The company has also established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office builds and further strengthen collaborations with global pharma/biotech partners and research institutes.

About Pregene Biopharma Co., Ltd

Shenzhen Pregene Biopharma Co. Ltd is a leading enterprise in the cell and gene therapy field with the core technology for industrialization. The companys core team comes from well-known institutions and companies including the Academy of Military Medical Sciences, the University of Toronto, and the US FDA.

Pregene has established the gene editing platform, viral vector and cell production platform, nanobody selection platform and other small to pilot trial manufacturing system, with total investment over 100 million CNY. It has the laboratories and GMP plants for cell and gene therapy of over 10,000 square meter.

The company focuses on the research and development of cell and gene therapy drugs, and participated in the drafting the national standard Considerations for CAR-T Cell Quality Study and Non-clinical Evaluation issued by the National Institutes for Food and Drug Control in June 2018. The CAR-T cell therapy for the treatment of multiple myeloma have obtained NMPA IND clearance as the Class I new drug, which is the first in China and fastest in the world using the humanized single domain antibody in CAR construct, and phase I clinical trials are now in progress. Other pipelines such as CAR-T, TCR-T and mRNA drugs for tumors, autoimmune diseases and other indications are in the development at different stages. The company has broad development prospects with the abundant backup technologies.

Looking forward to the future, the company will build the core capacity in one-stop solution for cell and gene therapy drugs, and fulfill the Express of innovative medicine development from drug discovery to clinical products.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement.

Bone Therapeutics core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics cell therapy products are manufactured to the highest GMP standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available atwww.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0)71 12 10 00investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries:BepublicCatherine HaquenneTel: +32 (0)497 75 63 56catherine@bepublic.be

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: +33 (0)1 44 71 94 94bone@newcap.eu

For US Media and Investor Enquiries:LHA Investor RelationsYvonne BriggsTel: +1 310 691 7100ybriggs@lhai.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Continued here:
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia -...

Recommendation and review posted by Bethany Smith

LONDON, UK / ACCESSWIRE / October 6, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the following update on its activities.

As previously announced, Hemogenyx Pharmaceuticals' CDX bi-specific antibody has the potential to treat Acute Myeloid Leukemia ("AML") directly as well as to provide a benign conditioning regimen for blood stem cell replacement therapy. The Company has now carried out extensive work developing treatments for AML and has to date obtained encouraging results.

As announced on 20 February 2020, the Company has constructed and successfully tested in vivo Chimeric Antigen Receptor ("CAR") programmed T cells ("HEMO-CAR-T") for the potential treatment of AML. HEMO-CAR was constructed using the Company's proprietary humanized monoclonal antibody against a target on the surface of AML cells.

It was also announced that the Company was engaging in additional engineering of HEMO-CAR-T cells to increase their safety and versatility. The Company has now introduced and successfully in vitro tested a safety switch within the HEMO-CAR. The aim of this safety switch is to modulate the activity of HEMO-CAR-T cells and to turn them into a "controllable drug" - SAFE-HEMO-CAR-T. The purpose of these efforts is to dramatically improve the safety and potential versatility of HEMO-CAR-T cells for the treatment of AML and/or conditioning of bone marrow transplants, as well as a number of additional potential indications.

Following the successful completion of these in vitro tests, in vivo tests of the efficacy of SAFE-HEMO-CAR-T against AML are being conducted using a model of AML established on the background of Advanced peripheral blood Hematopoietic Chimera (ApbHC) - humanized mice developed by Immugenyx, LLC, a subsidiary of Hemogenyx Pharmaceuticals. If these in vivo tests are successful, the Company will discuss its findings with its partners under the Sponsored Research Agreement with the University of Pennsylvania, announced on 11 August 2020, with a view to considering the inclusion of SAFE-HEMO-CAR-T in the program of pre-clinical trials currently underway there.

Dr Vladislav Sandler, Chief Executive Officer, commented, "We are encouraged by this new data which demonstrates our continuing progress in the development of novel treatments for blood cancers such as AML. The development of SAFE-HEMO-CAR-T further expands the Company's pipeline and advances it into a cutting-edge area of cell-based immune therapy. We are excited to have developed another unique product candidate that should, if successful, provide a new and potentially effective treatment for blood cancers for which survival rates are currently very poor."

About AML and CAR-T

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 25% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

CAR-T therapy is a treatment in which a patient's own T cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T cells from the patient, modifying the isolated T cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Enquiries:

Hemogenyx Pharmaceuticals plc

Home

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit http://www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:https://www.accesswire.com/609275/Hemogenyx-Pharmaceuticals-PLC-Announces-SAFE-HEMO-CAR-T-Effective-against-AML-in-vitro

See more here:
Hemogenyx Pharmaceuticals PLC Announces SAFE-HEMO-CAR-T Effective against AML in vitro - BioSpace

Recommendation and review posted by Bethany Smith

Hematopoietic Stem Cell Transplantation (HSCT) Market Scenario 2020-2026:

The Global Hematopoietic Stem Cell Transplantation (HSCT) market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2026. On the basis of historical data, Hematopoietic Stem Cell Transplantation (HSCT) market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Hematopoietic Stem Cell Transplantation (HSCT) industry is likely to appear as a commendable platform for emerging Hematopoietic Stem Cell Transplantation (HSCT) market investors.

This Hematopoietic Stem Cell Transplantation (HSCT) Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better.

Get Sample Report: https://grandviewreport.com/sample/63228

The complete value chain and downstream and upstream essentials are scrutinized in this report. Essential trends like globalization, growth progress boost fragmentation regulation & ecological concerns. This Market report covers technical data, manufacturing plants analysis, and raw material sources analysis of Hematopoietic Stem Cell Transplantation (HSCT) Industry as well as explains which product has the highest penetration, their profit margins, and R&D status. The report makes future projections based on the analysis of the subdivision of the market which includes the global market size by product category, end-user application, and various regions.

Topmost Leading Manufacturer Covered in this report:Escape Therapeutics Inc., Cryo-Save AG, Regen Biopharma Inc., CBR Systems Inc., ViaCord Inc., Lonza Group Ltd., Pluristem Therapeutics Inc., China Cord Blood Corp.

Product Segment Analysis: Allogeneic, Autologous

Application Segment Analysis:Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT), Cord Blood Transplant (CBT)

Get Discount @ https://grandviewreport.com/discount/63228

Regional Analysis For Hematopoietic Stem Cell Transplantation (HSCT)Market

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Market Synopsis:The market research report consists of extensive primary research, as well as an in-depth analysis of the qualitative and quantitative aspects by various industry specialists and professionals, to gain a deeper insight into the market and the overall landscape.

The objectives of the report are:

To analyze and forecast the market size of Hematopoietic Stem Cell Transplantation (HSCT)Industry in theglobal market. To study the global key players, SWOT analysis, value and global market share for leading players. To determine, explain and forecast the market by type, end use, and region. To analyze the market potential and advantage, opportunity and challenge, restraints and risks of global key regions. To find out significant trends and factors driving or restraining the market growth. To analyze the opportunities in the market for stakeholders by identifying the high growth segments. To critically analyze each submarket in terms of individual growth trend and their contribution to the market. To understand competitive developments such as agreements, expansions, new product launches, and possessions in the market. To strategically outline the key players and comprehensively analyze their growth strategies.

View Full Report @ https://grandviewreport.com/industry-growth/Hematopoietic-Stem-Cell-Transplantation-(HSCT)-Market-63228

At last, the study gives out details about the major challenges that are going to impact market growth. They also report provides comprehensive details about the business opportunities to key stakeholders to grow their business and raise revenues in the precise verticals. The report will aid the companys existing or intend to join in this market to analyze the various aspects of this domain before investing or expanding their business in the Hematopoietic Stem Cell Transplantation (HSCT) markets.

Contact Us:Grand View Report(UK) +44-208-133-9198(APAC) +91-73789-80300Email : [emailprotected]

More:
Hematopoietic Stem Cell Transplantation (HSCT) Market to eyewitness massive growth by 2026 | Escape Therapeutics Inc., Cryo-Save AG, Regen Biopharma...

Recommendation and review posted by Bethany Smith

The market research report on the Stem Cell Therapy Market provides a comprehensive analysis of the market dynamics, including development trends, application, types, competitive environment, value chain optimization, and region. Besides this, the report also provides key statistics on the Stem Cell Therapy Market status of the leading market players, key trends, and potential growth opportunities in the market.

The Stem Cell Therapy Market was valued at USD 117.66 Million in 2019 and is projected to reach USD 255.37 Million by 2027, growing at aCAGR of 10.97% from 2020 to 2027.

These study reports are designed with the goal to help the reader in favorable retrieve information and make decisions that are helpful to grow their business. Further, it also provides an examination of the economic synopsis, along with the benefits, drivers, restraints, production, supply, demand, and the level of market growth.

Get a Sample Copy of the Stem Cell Therapy Market Report with Latest Industry Trends @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113

The varying landscape for the overall Stem Cell Therapy industry is offered in the report providing a comprehensive pattern of the Stem Cell Therapy industry and its rapidly changing market landscape. The details mentioned in the report can assist the players in formulating strategies and approaches to gain a robust footing in the industry. Profitable insights and analytical data have been covered in the report to offer insight into global expansion strategies. Each key manufacturer and producer have been thoroughly assessed in the report.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The market report sheds light on the latest strategic developments and growth patterns of the market players to provide a clear view. The report is an investigative study that provides insights for the players to formulate their business expansion strategies and expand their footing in the market.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

Table of Content:

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the Stem Cell Therapy market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the Stem Cell Therapy market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the Stem Cell Therapy market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the Stem Cell Therapy market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market by Product: This section carefully analyzes all product segments of the Stem Cell Therapy market.

Market by Application: Here, various application segments of the Stem Cell Therapy market are taken into account for research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the Stem Cell Therapy market. The forecasts are also provided taking into consideration product, application, and regional segments of the Stem Cell Therapy market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the Stem Cell Therapy market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behavior and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the Stem Cell Therapy market.

Appendix: This is the last section of the report that focuses on data sources, viz. primary and secondary sources, market breakdown and data triangulation, market size estimation, research programs and design, research approach and methodology, and the publishers disclaimer.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/need-customization/?rid=24113

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: sales@verifiedmarketresearch.com

Read this article:
Stem Cell Therapy Market Growth Factors, Rising Trends and Outlook 2020 to 2027 - X Herald

Recommendation and review posted by Bethany Smith

Massachusetts-based AVROBIO announced today that it has entered an exclusive global license agreement, as well as a collaborative research funding agreement, with The University of Manchester. Together, the university and AVROBIO will look into an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.

The condition, which impacts an estimated one in 100,000 males worldwide, causes complications throughout the body and brain. Children with severe cases typically show symptoms beginning in their toddler years. At the moment, the standard of care is weekly enzyme replacement therapy, but it does not halt progression of the disease or address cognitive issues that may arise.

We believe a lentiviral gene therapy approach is well suited to treat a progressive and pervasive disease such as Hunter syndrome, which affects organs throughout the body and severely impairs cognitive function. If we treat children early, before their symptoms arise, we hope to prevent the tragic complications that rob these young children of their futures, said Geoff MacKay, AVROBIOs president and CEO. We believe our deep experience with investigational gene therapies for lysosomal disorders will enable us to efficiently move the program through clinical development in collaboration with Prof. Brian Bigger, who has done tremendous work to develop and optimize this investigational gene therapy. Were proud to add this program to our leading lysosomal disorder pipeline and excited about its potential to change the lives of patients and families living with Hunter syndrome.

The investigational gene therapy, titled AVR-RD-05, includes ex vivo transduction of the patients own hematopoietic stem cells with a therapeutic transgene. The transgene is meant to express functional enzymes that the patient needs to maintain cellular health. When reinfused back into the patient, the modified stem cells are designed to engraft in the bone marrow and produce generations of daughter cells, each carrying the transgene.

This is just one company looking toward making an impact in the MPS II realm as of late. REGENXBIO announced at the end of September that it was expanding its RGX-121 program, looking into the treatment of MPS II. RGX-121 is an investigational one-time gene therapy that uses the AAV9 vector to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme directly to the central nervous system.

An ongoing Phase I/II study is evaluating a single intracisternal administration of RGX-121 in severe instances of MPS II in patients under the age of five. As of Sept. 16, RGX-121 was reported to be well-tolerated in patients and there were no drug-related serious adverse events.

"MPS II is a serious and debilitating lysosomal disease that affects 1 in 100,000 children, and available treatments are inadequate to treat the neurodegenerative manifestations of the disease, said Terri Klein, President and Chief Executive Officer of the National MPS Society. Initiating a natural history study will increase the understanding of neurocognitive effects and key biomarkers of severe MPS II, and is critical to advancing the development of new treatment options. We are grateful for REGENXBIO's dedication to MPS and commitment to share the learnings from this observational study with the community.

REGENXBIO has also announced that the U.S. Food and Drug Administration cleared an Investigational New Drug application. The company plans on initiating a second Phase I/II multicenter, open-label trial of RGX-121 for the treatment of pediatric patients with severe MPS II between the ages of five and 18.

See the original post here:
AVROBIO and University of Manchester Enter Agreement for MPS II Research - BioSpace

Recommendation and review posted by Bethany Smith

A diagnosis of acute myeloid leukemia (AML) is particularly challenging in older adults, whose age makes them highly susceptible to the disease and treatment-related toxicity. To help patients and practitioners navigate the clinical decision-making process, the American Society of Hematology (ASH) convened an panel of experts who conducted a thorough review of the literature. The result of their work can be found in a new set of guidelines for the treatment of newly diagnosed AML in older adults.

Dr Mikkael Sekeres

Medscape spoke with Mikkael Sekeres, MD, chair of the ASH AML guideline panel and director of the Leukemia Program at Cleveland Clinic Taussig Cancer Institute. Sekeres shared the rationale behind the panel's key recommendations and the importance of keeping the patient's goals in mind.

Medscape: What is the average life expectancy of a 75-year-old developing AML compared with someone of the same age without AML?

Dr Sekeres: A 75-year-old developing AML has an average life expectancy measured in fewer than 6 months. Somebody who is 75 without leukemia in the United States has a life expectancy that can be measured in a decade or more. AML is a really serious diagnosis when someone is older and significantly truncates expected survival.

What is the median age at AML diagnosis in the United States?

About 67 years.

What are the biological underpinnings for poor outcomes in older AML patients?

There are a few of them. Older adults with AML tend to have a leukemia that has evolved from a known or unknown previous bone marrow condition such as myelodysplastic syndrome. Older adults also have worse genetics driving their leukemia, which makes the leukemia cells more resistant to chemotherapy. And the leukemia cells may even have drug efflux pumps that extrude chemotherapy that tries to enter the cell. Finally, older adults are more likely to have comorbidities that make their ability to tolerate chemotherapy much lower than for younger adults.

In someone who is newly diagnosed with AML, what initial options are they routinely given?

For someone who is older, we divide those options into three main categories.

The first is to take intensive chemotherapy, which requires a 4-6 week hospitalization and has a chance of getting somebody who is older into a remission of approximately 50% to 60%. But this also carries with it significant treatment-related mortality that may be as high as 10% to 20%. So, I have to look my older patients in the eyes when I talk about intensive chemotherapy and say, "There is a 1 in 10 or 1 in 5 chance that you might not make it out of the hospital alive."

The second prong is lower-dose therapy. While the more-intensive therapy requiring hospitalization does have a low, but real, chance of curing that person, less-intensive therapy is not curative. Our best hope with less-intensive therapy is that our patients enter a remission and live longer. With less-intensive therapy, the chance that someone will go into remission is probably around 20%, but again it is not curative. The flip side to that is that it improves a person's immediate quality of life, because they're not in the hospital for 4 to 6 weeks.

The final prong is to discuss palliative care or hospice upfront. We designed these guidelines to be focused on a patient's goals of therapy and to constantly revisit those goals to make sure that the treatment options we are offering are aligning with them.

The panel's first recommendation is to offer antileukemic therapy over best supportive care in patients who are appropriate candidates. Can you provide some context for this recommendation?

Doesn't that strike you as funny that we even have to make a recommendation about getting chemotherapy? Some database studies conducted over the past two decades show that, as recently as 15 years ago, only one third of patients who were over the age of 65 received any type of chemotherapy for AML. More recently, as we have had a few more drugs available that allow us to use lower-dose approaches, that number has crept up to probably about 50%. We still have half the patients offered no therapy at all. So, we felt that we had to deliberately make a recommendation saying that, if it aligns with a patient's goals, he or she should be offered chemotherapy.

The second recommendation is that patients considered candidates for intensive antileukemic therapy should receive it over less-intensive antileukemic therapy. How did you get to that recommendation?

There is a debate in our field about whether older adults should be offered intensive inpatient chemotherapy at all or whether we should be treating all of them with less-intensive therapy. There are not a huge amount of high-quality studies out there to answer some of these questions, in particular whether intensive chemotherapy should be recommended over less-intensive therapy. But with the available evidence, what we believe is that patients live longer if they are offered intensive antileukemic chemotherapy. So, again, if it aligns with a patient's goals, we support that patient receiving more-intensive therapy in the hospital.

What does the panel recommend for patients who achieve remission after at least a single cycle of intensive antileukemic therapy and who are not candidates for allogeneic hematopoietic stem cell transplantation?

Once again, this may seem at first blush to be an obvious recommendation. The standard treatment of someone who is younger with AML is to offer intensive inpatient chemotherapy to induce remission. This is followed by a few cycles of chemotherapy, mostly in an outpatient setting, to consolidate that remission.

What is the underlying philosophy for this approach?

Every time we give chemotherapy, we probably get about a 3 to 4 log kill of leukemia cells. Imagine when a person first presents with AML, they may have 10 billion leukemia cells in his or her body. We are reducing that 3 to 4 log with the first course of chemotherapy.

When we then look at a bone marrow biopsy, it may appear to be normal. When leukemia is at a lower level in the body, we simply can't see it using standard techniques. But that doesn't mean the leukemia is gone. For younger patients, we give another cycle of chemotherapy, then another, then another, and then even another to reduce the number of leukemia cells left over in the body until that person has a durable remission and hopefully cure.

For someone who is older, the data are less clear. While some studies have shown that if you give too much chemotherapy after the initial course, it doesn't help that much, there is a paucity of studies that show that any chemotherapy at all after the first induction course is helpful. Consequently, we have to use indirect data. Older people who are long-term survivors from their acute leukemia always seem to have gotten more than one course of chemotherapy. In other words, the initial course of chemotherapy that a patient receives in the hospital isn't enough. They should receive more than that.

What about older adults with AML considered appropriate for antileukemic therapy but not for intensive antileukemic therapy?

This again gets to the question of what are a patient's goals. It takes a very involved conversation with a person at the time of their AML diagnosis to determine whether he or she would want to pursue an aggressive approach or a less-aggressive approach. If a person wants a less-aggressive approach, and wants nothing to do with a hospital stay, then he or she is also prioritizing initial quality of life. In this recommendation, based on existing studies, we didn't have a preference for which of the available less-aggressive chemotherapies a person selects.

There's also debate about what to do in those considered appropriate for antileukemic therapy, such as hypomethylating agents (azacitidine and decitabine) or low-dose cytarabine, but not for intensive antileukemic therapy. What did the available evidence seem to indicate about this issue?

There have been a lot of studies trying to add two drugs together to see if those do better than one drug alone in patients who are older and who choose less-intensive therapy. The majority of those studies have shown no advantage to getting two drugs over one drug.

Our recommendation is that in these situations a patient gets one drug, not two, but there are a couple of caveats. One caveat is that there has been a small study showing the effectiveness of one of those low-dose chemotherapies combined with the drug glasdegib. The second caveat is that there have been results presented combining one of these low-dose chemotherapies with the drug venetoclax. One of those was a negative study, and another was a positive study showing a survival advantage to the combination vs the low-dose therapy alone. We had to couch our recommendation a little bit because we knew this other study had been presented at a conference, but it hadn't come out in final form yet. It did recently, however, and we will now revisit this recommendation.

The other complicated aspect to this is that we weren't 100% convinced that the combination of venetoclax with one of these lower-dose therapies is truly less-intensive therapy. We think it is starting to creep up toward more-intensive chemotherapy, even though it is commonly given to patients in the outpatient setting. It gets into the very complicated area of what are we defining as more-intensive therapy and less-intensive therapy.

Is there a recommended strategy for older adults with AML who achieve a response after receiving less-intensive therapy?

This is also challenging because there are no randomized studies in which patients received less-intensive therapy for a finite period of time vs receiving those therapies ad infinitum. Given the lack of data and also given a lot of anecdotal data out there about patients who stopped a certain therapy and relapsed thereafter, we recommended that patients continue the less-intensive therapy ad infinitum. So as long as they are receiving a response to that therapy, they continue on the drug.

Of course, there are also unique considerations faced by older patients who are no longer receiving antileukemic therapy, and have moved on to receiving end-of-life care or hospice care. What advice do the guidelines offer in this situation?

There are a lot of aspects of these recommendations that I think are special. The first is the focus on patient goals of care at every point in these guidelines. The second is that the guidelines follow the real disease course and a real conversation that doctors and patients have at every step of the way to help guide the decisions that have to be made in real time.

A problem we have in the United States is that once patients enter a hospice, most will not allow blood transfusions. One reason is that some say it is antithetical to their philosophy and consider it aggressive care. The second reason is that, to be completely blunt, economically it doesn't make sense for hospices to allow blood transfusions. The amount that they are reimbursed by Medicare is much lower than the cost of receiving blood in an infusion center.

We wanted to make a clear recommendation that we consider transfusions in a patient who is in a palliative care or hospice mode to be supportive and necessary, and that these should be provided to patients even if they are in hospice, and as always if consistent with a patient's goals of care.

How does a patient's age inform the discussion surrounding what intensity treatment to offer?

With younger adults, this is not as complicated a conversation. A younger person has a better chance of being cured with intensive chemotherapy and is much more likely to tolerate that intensive chemotherapy. For someone who is younger, we offer intensive chemotherapy and the chance of going into remission is higher, at 70% to 80%. The chance of dying is lower, usually less than 5%. It is an easy decision to make.

For an older adult, the riskbenefit ratio shifts and it becomes a more complicated option. Less-intensive therapy or best supportive care or hospice become viable.

Are there other factors confounding the treatment decision-making process in older adults with AML that practitioners should consider?

Someone who is older is making a different decision than I would. I have school-aged children and believe that my job as a parent is to successfully get them to adulthood, so I would take any treatment under the sun to make sure that happens. People who have lived a longer life than I have may have children and even grandchildren who are adults, and they might have different goals of care. My goals are not going to be the same as my patient's goals.

It is also harder because someone who is older may feel that he or she has lived a good life and doesn't need to go through heroic measures to try to be around as long as possible, and those goals may not align with the goals of that person's children who want their parent to be around as long as possible. One of the confounding factors in this is navigating the different goals of the different family members.

Dr Sekeres has disclosed no relevant financial relationships.

Kate O'Rourke is a freelance writer in Portland, Maine. She has covered the field of oncology for over 10 years.

For more news, follow Medscape on Facebook, Twitter, Instagram, andYouTube.

Continued here:
A Uniquely Patient-Focused Take on Treating AML in Older Adults - Medscape

Recommendation and review posted by Bethany Smith

WASHINGTON Heres a look at how Georgias members of Congress voted over the previous week.

Along with its roll call votes this week, the House also passed the Cyber Sense Act (H.R. 360) to require the Secretary of Energy to establish a voluntary Cyber Sense program to test the cybersecurity of products and technologies intended for use in the bulk-power system; the Consumer Product Safety Inspection Enhancement Act (H.R. 8134) to support the Consumer Product Safety Commissions capability to protect consumers from unsafe consumer products; the School-Based Allergies and Asthma Management Program Act (H.R. 2468) to increase the preference given in awarding certain allergies and asthma-related grants to states that require certain public schools to have allergies and asthma management programs; and the Effective Suicide Screening and Assessment in the Emergency Department Act (H.R. 4861) to establish a program to improve the identification, assessment and treatment of patients in the emergency department who are at risk of suicide.

DISCLOSING TIES TO UYGHUR LABOR: The House has passed the Uyghur Forced Labor Disclosure Act (H.R. 6270) sponsored by Rep. Jennifer Wexton, D-Va., to require publicly traded companies to disclose whether they have business ties to Chinas Uyghur Autonomous Region in Xinjiang province. Wexton said the requirement would let investors know of a given companys passive complicity or active exploitation of one of the most pressing and ongoing human rights violations of our lifetime. A bill opponent, Rep. Anthony Gonzalez, R-Ohio, said it wrongly tried to have the Securities and Exchange Commission police human rights violations, a role that would be better handled by the Treasury Department. The vote, on Sept. 30, was 253 yeas to 163 nays.

NAYS: Loudermilk R-GA (11th), Allen R-GA (12th), Scott, Austin R-GA (8th), Collins R-GA (9th), Carter R-GA (1st), Woodall R-GA (7th), Ferguson R-GA (3rd), Hice R-GA (10th)

YEAS: Bishop D-GA (2nd), Scott, David D-GA (13th), McBath D-GA (6th), Johnson D-GA (4th)

NOT VOTING: Graves R-GA (14th)

PRESIDENTIAL ELECTION: The House has passed a resolution (H. Res. 1155) sponsored by Rep. Eric Swalwell, D-Calif., reaffirming the Houses commitment to an orderly and peaceful transfer of presidential power after the November election. Swalwell said: The peaceful transition of power is not only a bedrock principle of Americas founding, it is a living ideal that we must exercise and pass down to our children. An opponent, Rep. Matt Gaetz, R-Fla., called the resolution a way for Democrats to attack the president and disguise the fact that they will refuse to accept the election results unless they win. The vote, on Sept. 29, was 397 yeas to 5 nays.

YEAS: Entire delegation, except Collins R-GA (9th), Graves R-GA (14th), who did not vote

DISEASE THERAPIES: The House has passed the Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act (H.R. 4764) sponsored by Rep. Doris O. Matsui, D-Calif. The bill would reauthorize a program for transplanting umbilical cord blood, stem cells, and bone marrow to adults and children suffering from various diseases. The vote, on Sept. 30, was unanimous with 414 yeas.

Success! An email has been sent to with a link to confirm list signup.

Error! There was an error processing your request.

YEAS: Entire delegation, except Graves R-GA (14th), who did not vote

FURTHER COVID-19 SPENDING: The House has approved an amendment to the Americas Conservation Enhancement Act (H.R. 925). The amendment would spend $2.2 trillion on new COVID-19 measures, including testing and treatment efforts and unemployment benefits. A supporter, Rep. James P. McGovern, D-Mass., said the spending was needed for families to pay for necessities like food, utilities, and rent during this pandemic. An opponent, Rep. Tom Cole, R-Okla., said the amendment had been hurriedly brought to the floor without minority input or adequate time for review, and that it would not pass the Senate. The vote, on Oct. 1, was 214 yeas to 207 nays.

NOT VOTING: Loudermilk R-GA (11th), Graves R-GA (14th)

YEAS: Bishop D-GA (2nd), Scott, David D-GA (13th), McBath D-GA (6th), Johnson D-GA (4th)

NAYS: Allen R-GA (12th), Scott, Austin R-GA (8th), Collins R-GA (9th), Carter R-GA (1st), Woodall R-GA (7th), Ferguson R-GA (3rd), Hice R-GA (10th)

CONTINUING APPROPRIATIONS: The Senate has passed the Continuing Appropriations Act and Other Extensions Act (H.R. 8337) sponsored by Rep. Nita M. Lowey, D-N.Y., to extend through Dec. 11 funding for health programs, including Medicare, surface transportation, and many other government programs. The vote, on Sept. 30, was 84 yeas to 10 nays.

AFFORDABLE CARE ACT LITIGATION: The Senate has rejected a cloture motion to end debate on a motion to consider a bill (S. 4653) sponsored by Senate Minority Leader Chuck Schumer, D-N.Y., that would block the Justice Department from making arguments in court for cancelling any provision of the 2010 health care reform law (ACA). The vote to end debate on Oct. 1, was 51 yeas to 43 nays, with a three-fifths majority needed for approval.

See the rest here:
Congress Votes | News | albanyherald.com - The Albany Herald

Recommendation and review posted by Bethany Smith

Are you apprehensive about too much hair in your comb and shower, leading to a reduced hair volume and baldness? Does thinning of hair run in your family? Is hair loss a big concern for you? Is it messing with your confidence?

Then you are at the right spot. This article goes in-depth and discusses some key concepts linked to hair loss and technique to prevent it.

The Hair Growth Cycle

In order to achieve the desired hair length, some people either trim their hair regularly or leave them out to grow. Regardless, the hair growth cycle remains undisputed.

Your hair consists of a hair follicle and shaft. Present underneath the scalp, the hair follicle provides anchorage to the hair into the scalp. The hair shaft is the strand of hair made up of proteins. There are three phases of the hair growth cycle.

1. The Anagen Phase

The first phase is called the Anagen phase and corresponds to the growth period. During this phase, rapid cell division occurs in the hair follicles bulb, resulting in the growth of the hair strand. The hair length increases at the roots, with active growth for 2 to 7 years before the dormant period of the hair follicle is reached. During this period, the hair strand can lengthen from 18 to 30 inches long. The final length of the hair varies from individual to individual depending upon their genetic makeup, health, age, and other factors.

2. The Catagen Phase

The Catagen phase in the hair growth cycle is short and lasts for about 2 to 3 weeks. This is the transitional period during which the growth of hair stops, and it gets disconnected from the blood supply. This type of hair is called a club hair.

3. The Telogen Phase

The final stage of hair growth, the Telogen Phase, starts with a resting period and lasts for about 2 months. During this period, the club hair is in the resting phase, and new hair starts to grow beneath it.

Subsequently, the resting club hair falls out, letting the new hair strand to emerge from the scalp. This falling of hair is natural, usually doesnt get noticed, and thus shouldnt be alarming. The typical rate of hair shedding per day is 50 to 100 strands. Every hair strand undergoes the growth phase separately at different timings; thus, you wont notice hair loss in patches simultaneously.

What Is DHT?

Androgenic alopecia, also known as male or female pattern baldness, is a widespread cause behind male and female hair thinning. Although highly prevalent in women, it is more common in men. On average, around 30 million women and 50 million men in the U.S. suffer from this condition.

The phenomenon of alopecia is aggravated by the activity of sex hormones in the body, thereby called androgenic alopecia. One of the androgens responsible for this mechanism is Dihydrotestosterone (DHT), which brings about the development of male sex characteristics.

How Is DHT Produced In The Body?

DHT is produced in your body as a byproduct of the sex hormone, testosterone. 5-Reductase is the enzyme that breaks down about 10% of testosterone into DHT in tissues, including skin, prostate, liver, and hair follicles. While DHT results in body hair growth, it interestingly leads to loss of scalp hair faster and earlier in life. Consequently, blocking this androgen is what makes hair loss therapies effective in preventing hair fall.

How Does DHT Impact The Hair Follicles And Cause Miniaturization?

Researchhas shown that hair follicle miniaturization is the conversion of hair from terminal to vellus type. This process occurs at the follicular level when anagen to telogen ratio reduces, thereby increasing hair loss. It means that the anagen (growth) phases duration is reduced while the telogen phase is prolonged.

Male or female pattern hair loss occurs due to the shortening of the growth phase, which takes place with the miniaturization of the follicles. This signifies that hair cannot grow as long as it would have otherwise grown.

The anagen phase gradually narrows down so much that the new hair does not emerge from the scalp. Telogen hair type is poorly anchored in the scalp, allowing it to fall out easily.

The small-sized follicles lead to thinner hair shafts with each growth cycle. The hair eventually becomes vellus type soft and light hair type present on an infants body.

How Is DHT Blocked To Prevent Hair Loss?

Fortunately, the action of DHT can be blocked by compounds known as DHT blockers. DHT-blocking products include shampoos and oils containing DHT-blocking ingredients like biotin, saw palmetto, ketoconazole, etc. These agents decrease the production of the Alpha-5 Reductase enzyme, which then inhibits the formation of DHT. A combination of these active ingredients in shampoos and oils works by reducing the excess amount of DHT. Thus, it produces a favorable environment for hair growth.

Finasteride (generic name: Propecia) is also a proven DHT blocker. It is a prescription tablet that works well in preventing hair loss and receding hairlines. Finasteride binds to the 5-Reductase enzyme, leading to the inhibition of DHT production.

Using DHT-Blockers To Prevent Hair Loss

The phenomena of hair thinning in males and females occur due to numerous reasons, including underlying health conditions. However, genetics is the most significant factor in male and female pattern hair loss. DHT is another crucial player in causing male or female pattern baldness and must be blocked by using products containing proven DHT-blockers. For example, Hair Restoration Laboratories has a Hair Restore line of products that utilized what the company calls its DHT Halting Technology. Its lineup of shampoos, conditioner and serums contain a boatload of ingredients, such as saw palmetto, caffeine, green tea extract, pumpkin seed oil, and others that are clinically proven to help block DHT when applied topically. By helping to block DHT from attacking your hair follicles, male and female pattern hair loss can be prevented and your follicles can grow new and thicker hair.

In sum, if you wish to halt the progression of alopecia, you need to address and counter that adverse impact of DHT. If not kept in check, androgen alopecia will continue to progress and become worse with time.

References:

1. Ellis K. Hair growth cycle The 3 stages explained. The Hair Lab. (2018). https://www.growgorgeous.co.uk/blog/the-hair-lab/how-does-hair-grow/

2. Anonymous. (August 2020). Androgenetic alopecia. Genetics Home Reference. https://ghr.nlm.nih.gov/condition/androgenetic-alopecia

3. Jewell T. What You Need to Know About DHT and Hair Loss. (January 2019). Healthline. https://www.healthline.com/health/dht#purpose-and-function

4. Levy B. DHT and Male Hair Loss Explained. Hims. (September 2017). https://www.forhims.com/blog/dht-and-male-hair-loss-explained

5. Ravi A. The Best DHT Blockers & How They Can Combat Hair Loss. (July 2020). https://skinkraft.com/blogs/articles/what-is-dht

View post:
Everything About Hair Loss & DHT - The Ritz Herald

Recommendation and review posted by Bethany Smith

Philip Patterson who is responsible for the day to day management of the herd with herdsman, Scott Cromwell, right

In recent years Philip Patterson has been responsible for the day to day running of the milking herd - he has always been keen to try new and innovative ways to manage the herd.

The 300 strong herd of Holsteins have been AI bred for the last four years using a mixture of proven and genomic sires from Genus ABS. Philip has taken the breeding policy a step further during the last 18 months, moving to a full Sexcel and beef strategy and employing a new herdsman to assist with the breeding of the cows, Scott Cromwell.

Sexcel is the name given to Genus ABSs proprietary technology for sexing bovine semen. This innovative technology does not subject the cells to the high pressures, electric currents and shear forces used to produce the sexed semen historically available to farmers. The result has been a superior sexed genetics product that has helped customers maximize their profitability in line with their individual economic herd goals.

Genus ABS have concentrated on developing a product with superior fertility. Data from UK RMS herds, based on 169,693 inseminations, has shown that the Relative Conception Rate (RCR) on maiden heifers is 92% and the improved performance from Sexcel is reaching as high as 94% in 3rd lactation cows. This data set has also shown that Sexcel has delivered up to a 92% skew rate, thats 92 female calves in every 100 born. So more pregnancies per service as well as more females per calving with Sexcel over any other sexed product.

Philip commented: I was keen to try Sexcel to minimise the number of low value Holstein bull calves using the very latest technology available. I started using it in February 2019 and have been extremely pleased with the results. The conception rates have been similar to what we were achieving with conventional semen.

Although the beef income will be important, the British Blue sires are selected to ensure that the cows calve down successfully and start milking well, so particular attention is paid to calving ease when selecting beef bulls.

Gareth Bell, Genus ABS, who works closely with Phillip said: We are aiming to create cows that are well balanced with a willingness to produce high volumes of milk. PLI is followed closely and with Genus having 20 of the top 30 PLI sires, there are lots of options when it comes to choosing sires that will leave more profit in the herd.

The Pattersons herd also uses Genus ABS to help with the day to day management of the herd, through the ABS Partner programme. Action lists are created on a weekly basis to aid with dry offs and also any fertility work carried out. These reports are then used by Scott to monitor the herds reproductive performance and highlight any areas that need attention.

The management reports have helped us become more structured in our approach to fertility. We can see the benefits of the improvements we have made, including increasing the herds overall conception rate and reducing the calving interval, said Scott.

For more information on Sexcel or other Genus ABS products please contact your local Genus ABS representative or the office on 028 38 334426.

More here:
Sexcel The basis of a new plan! - Farming Life

Recommendation and review posted by Bethany Smith

Its this time of the year when those of us in northern temperate zones are spectators of a fascinating natural phenomenon the appearance of autumn leaf colors.

The leaves start to change colors as they age, or senesce. During this period a cluster of enzymes in the leaves start chewing up their green pigment, called chlorophyll. As the leaves become less green, their red, yellow, and orange pigments (known as anthocyanins and carotenes) begin to shine. However, exactly how chlorophyll breakdown works is still only partially understood.

While autumn leaves are a great example of chlorophyll breakdown, evergreen plants (those that remain green all year long), vegetables, and fruits also experience chlorophyll decay. However, this happens only under special conditions such when fruit ripen or when evergreen plants are deprived of nutrients and water.

Banana skin is one of the few fruits where chlorophyll degradation can be mapped under ultraviolet (UV) light. As bananas ripen, their skins lose their green color a sign of chlorophyll breakdown and form new pigments that fluoresce blue under the UV light. Scientists know that this new pigment, known as hypermodified fluorescent chlorophyll catabolite (hmFCC), is produced very briefly in most plants. Banana skins and grapevine leaves are known to produce hmFCCs for a longer period.

Recently scientists at Instituto de la Grasa, Spain analyzed devils ivy, an evergreen plant, in their quest to find signs of this fluorescent compound. They activated the aging process by starving the plant, and voila! Exposure to UV light produced the blue, fluorescent pigment hmFCC. The team also observed two other newly identified compounds that will provide more insights into the evergreen chlorophyll breakdown puzzle.

Although the actual benefit of producing this blue, fluorescent compound is still a mystery, scientists think that it could provide protection against radiation or function in communication between animals and plants.

View post:
Scientists use 16 genes to distinguish between two types of lethal pancreatic cancer - Massive Science

Recommendation and review posted by Bethany Smith

Its one of the most important genes in biology: Sry, the gene that makes males male. Development of the sexes is a crucial step in sexual reproduction and is essential for the survival of almost all animal species.

Today in the journal Science, my international collaborators and I report the surprise discovery of an entirely new part of the Sry gene in mice a part we had no idea existed.

I co-discovered Sry in 1990. It is the gene on the Y (male) chromosome that leads to the development of male characteristics in mice, humans and most other mammals. Since then, Sry has been the subject of intense study worldwide because of its fundamental role in mammalian biology.

We have come to understand, in some detail, how Sry acts to trigger a cascade of gene activity that results in the formation of testes, instead of ovaries, in the embryo. Testes then stimulate the formation of other male characteristics.

But its clear we dont have all the answers just yet. Our results published today take us one step further in the right direction.

For 30 years, we have understood the Sry gene is made up of one exon, a segment of a gene used to code for amino acids, the building blocks of proteins. This can be compared to a computer file consisting of one contiguous block of data, on a hard disk.

Our newest research reveals theres actually a second exon in mouse Sry. This is like finding a whole new separate block of previously hidden data.

The mouse genome, like the human genome, has been extensively characterised due to the availability of advanced DNA sequencing and related technologies. Researchers commonly assume all the genes and all the parts of the genes have already been discovered.

But earlier this year, scientists in Japan uncovered what looked like a new piece of the Sry gene in mice. New sequencing approaches revealed what appeared to be two versions of Sry: a short, single-exon form and a longer, two-exon form. They called this two-exon version Sry-T.

They collaborated with my group at the University of Queensland and removed the new exon using CRISPR, a gene editing tool that lets researchers alter DNA precisely. Together we discovered this prevented Sry from functioning: XY mice (which would normally develop as males) developed as females instead.

Conversely, adding Sry-T to fertilised XX mouse eggs (which would normally develop as females) resulted in males.

On the left, an XY mouse lacking Sry-T that developed as female. On the right, an XX mouse carrying the Sry-T gene that developed as male. Makoto Tachibana, Osaka University, Author provided

Importantly, although human Sry does not have the added exon, our discovery may reveal new functions that might be shared between mouse and human Sry.

The DNA sequence of the new exon in Sry-T may point us towards discovering some of the genes and proteins that interact with Sry, something that has been elusive up till now.

And interactions we find in mice may also occur in humans. Studying what human Sry interacts with may help explain some cases of differences in human sex development, otherwise known as intersex development. This is a common but poorly understood group of mostly genetic conditions that arise in humans.

Intersex refers to people who are born with genetic, hormonal or physical sex characteristics that are not typically male or female. Shutterstock

Currently, we dont know the genetics behind a large proportion of intersex conditions. This is partly because we dont yet know all the genes involved in the human sex development pathway.

Scientifically, this discovery is a bit like discovering a new cell type in the body, or a new asteroid in the Kuiper belt. As with many scientific discoveries, it challenges what we thought we knew and raises many questions.

What is the function of the new exon in Sry-T?

Currently, we only have part of the answer. It turns out the first exon of Sry, the one we already knew about, contains instability sequences at its end. These are sequences that cause proteins to fray and degrade.

An important function of the newly discovered second exon is to mask the instability sequences, seal the end of the Sry protein and prevent it from degrading. In other words, this second exon is crucial to the development of male babies.

Whats more, this protection mechanism represents an unusual and intriguing evolutionary mechanism that has acted to help stop vulnerable Y-chromosome genes from literally falling apart.

But its early days yet. The challenge now is to understand whether there are more functions hidden within the newly discovered exon.

If so, this information may provide some of the missing links that have stood in the way of our full understanding of how Sry works at a molecular level and of how males and females come to be.

Peter Koopman, Professorial Research Fellow, The University of Queensland

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read this article:
We Discovered a Missing Gene Fragment Thats Shedding New Light on How Males Develop - Gizmodo Australia

Recommendation and review posted by Bethany Smith

You wouldnt eat a food that shrinks your brain. You wouldnt drive a car that makes you sweat. You wouldnt buy a purse that worsens PMS. So why are we all so cool with stress being just a part of life? It doesnt have to be. And if you reduce stress, you will be better for it. Because the impact stress has on your body is remarkableand hazardous. Read on to discover 30 more things stress is doing to your bodyand to ensure your health and the health of others, dont miss these Sure Signs Youve Already Had Coronavirus.

1

Your head is more likely to throb when youre stressed, according to the Mayo Clinic, with a tension-type headache or even a migraine. And feeling under pressure is also likely to make your headaches worse.

2

Stress kicks your body into its fight or flight mode, ramping up the release of certain hormones and preparing you to deal with danger. The result can sometimes be hands that shake like maracas.

3

Were not kidding. When were stressed, our body releases the hormone cortisol, and in limited doses, it can actually be beneficial. But studiesincluding one at the University of California at Berkeleyhave shown that chronic stress actually decreases the weight and volume of the brain.

4

Stress can increase the production of stomach acid, leading to that annoying reflux, as acid irritates the esophagus. And if you already suffer from chronic heartburn, stress can make it worse. A study of nearly 13,000 sufferers published in Internal Medicine discovered that nearly half reported stress as the biggest factor that worsened symptoms.

5

Stress gets us all riled up and causes hyper-arousal, making it difficult to fall asleep, stay asleep and making the quality of our sleep worse.

Recommendation: The National Sleep Foundation suggests a cooling off period before bed time, which allows the brain to wind down. Two hours should do it. Put your work away, turn off the TV and grab a book or listen to music.

Story continues

RELATED: Doing This Just Minutes a Day Helps You Sleep Better

6

When youre stressed, the muscles responsible for breathing tense up, making it more difficult to catch your breath.

Recommendation: If you begin to feel panicky and short of breath, start by exhaling deeply, emptying your lungs. You can also try breathing through your nose, which automatically slows your breathing.

7

If it seems like youre more likely to be sick when youre stressed, you may not be imagining it. Studies have shed light on the link between stress and sickness, finding that those living with chronic stress (such as unemployment or caregiving to a dementia patient) had a suppressed immune system that left them more vulnerable to the flu and a host of other illnesses.

RELATED: 20 Reasons Why You Keep Getting Sick

8

When were under stress, our hearts beat faster to help blood reach our vital organs. Often its harmless, but it may not be for those suffering chronic stress. One study from the European Society of Cardiology found that people with stressful jobsnurses or bus drivers, for examplehad a 48% higher risk of atrial fibrillation, a condition marked by an irregular, often rapid heart beat.

9

Stress has been shown to cause reproductive problems in both men and women. In one study published in Fertility and Sterility, researchers tested 274 women who were trying to get pregnant and found that those with higher levels of a particular enzyme in their saliva correlated to stress had a 12% more difficult time getting knocked up.

10

Erectile dysfunction is complicated and can have physical as well as psychological causes. Science, however, has shown over and over that stress tends to make the condition worse by releasing more adrenaline and causing exaggerated contractions of the muscles in the penis, keeping it from filling with blood.

11

Research has shown that various kinds of stress can wreak havoc on a womans period, making it irregular or disappear altogether. And to make matters worse, the Eunice Kennedy Shriver National Institute of Child Health and Human Development studied 259 women and found that stress can also make PMS pain worse.

12

And its true in both men and women. The causes, a study shows, can be both physical and psychological. Stress causes hormonal changes in the body, which arent particularly conducive for getting it on. It also makes someone distracted, and when their mind is on something else, sex can take a back seat.

Recommendation: One way to break the no-sex cycle is to get more physical with your partner, according to the Gottman Institute. It simply forces the body to go from stress to relaxation, if you allow this. Kiss your stressed out partner a little bit more and hug them for 20 seconds longer.

13

Stress gets your heart pumping faster and spikes your blood pressure. Not good. Usually, the response in temporary, a reaction to a particular stressful event. But chronic stress over long periods of time can cause inflammation in the arteries, which could lead to a heart attack down the road.

Recommendation: Try some good ol fashioned exercise. Working out three to five times a week can reduce your stress and will make a difference long-term in lowering your blood pressure, according to the Mayo Clinic.

14

When youre stressed, your body behaves as if its under attack, and your liver reacts by releasing more glucose into your bloodstream. Ongoing stress can lead to long-term sugar spikes, putting you at risk of type 2 diabetes, say experts.

15

Your gut has the most nerves in your body, this side of your brain, and stress can adversely affect your entire digestive system. The hormones released when youre stressed can interfere with digestion and harm the microorganisms living in your digestive tract. Cue indigestion, cramps, nausea and a whole host of other GI issues.

16

That tightening can cause back aches and other ailments.

Recommendation: Next time youre feeling stressed, reach for the walnuts. Researchers have shown that foods containing polyunsaturated fats, like the nuts, may help us deal better with stress.

RELATED: This Can Be the First Sign of COVID, Study Finds

17

Stress can lead to a dry mouth in several ways, say experts. Anxious people tend to breathe through their mouths, drying out the inside. The acid reflux associated with stress can also have an affect on the salivary glands and keep them from producing as much.

18

Chronic stress can leave your feeling zapped of energy. It could be the accompanying insomnia, or some theorize that it might have something to do with exhausting your adrenal glandthough a 2016 review of the research debunked that diagnosis.

19

We sweat more when were stressed and we sweat differently, studies show. Anxiety causes sweat to be produced from the apocrine glands, which secrete a thicker, milkier sweat than our eccrine glands. The downside: sweat from the apocrine glands tends to stink more.

20

Getting headaches is one thing, but actually altering your genetic code? Yep. Researchers at the University of Copenhagen have found that stress can switch on genes that werent supposed to be switched on. The consequence is that genes that should be turned off are now active and this may disturb cellular development, identity and growth, the researcher said.

RELATED: The Scariest New Symptoms of COVID-19

21

A study at Johns Hopkins concluded that long-term stress may affect the way that the genes controlling mood and behavior are expressed, leading a stressed-out person to be at a higher risk of depression. Tests on mice found that stress led to an increase in a protein produced by a gene called Fkbp5, which in humans has been linked to depression and bipolar disease.

22

Are the strains and demands of modern society commonly exceeding human ability? Thats the question asked by the authors of this study of more than 17,000 working adults in Stockholm, Sweden. The scientists found that even mild stress can lead to long-term disability or an inability to work. Those who experienced mild stress were 70% more likely to collect disability benefits.

23

Watch out. Men who are moderately or highly stressed for a number of years were found to have a 50 percent higher mortality rate, according to the Journal of Aging Research. The good news is that two very stressful situations a year might actually be beneficial, teaching us to cope with adversity. Anything beyond that, however, and it might be an early grave.

24

There may be something to that cliche about stress eating. Researchers at University College London found that feeling stressed changes what we eat. Those under pressure didnt necessarily eat more, but they did reach for more sweet, fatty foods than usual.

Recommendation: If youre feeling stressed, be more aware of what youre eating and try to curb your consumption of junk foodno matter how much your brain is screaming that you need it. For food solutions, visit eatthis.com.

25

One of those areas of the brain that gets shrunken by stress is the hippocampus, which plays a big part in learning and memory. A 2018 study found that those with higher levels of the stress hormone cortisol did worse on memory tests, especially women.

26

Research has shown that periods of mild to moderate stress may actually help the brain to better encode memories and improve learning. For example, a college student freaked out about an upcoming midterm may actually retain the material better and ace the test.

RELATED: 38 Ways Youre Treating Your Heart Wrong

27

In addition to generally suppressing the immune system, stress can lead to the growth of malignant cells, making a cancerous tumor bigger, says one study.

28

Children of parents with drinking problems face a greater risk of turning to booze after experiencing stressful situations, a University of Gothenburg study found.

Recommendation: If alcohol relaxes you when youre stressed, then you should try to find other ways of calming yourself downrelaxation exercises, for example, the researcher suggests.

29

Tinnitus, that same kind of annoying ringing you get after, say, sitting through a Metallica concert, might just be induced by stress. One study by the Egypts Minia University found that those suffering from chronic ringing tended to be more stressed. In short, There is a direct correlation between duration of tinnitus and severity of stress.

30

It doesnt get more serious than that. Severe mental stress can bring on sudden cardiac death, as medical professionals colorfully call it. In particular, suffering through a traumatic event, such as an earthquake or a war strike, can be so stressful that people literally keel over.

Recommendation: Dont worry. No ones ever died of a panic attack. If youre experiencing anxiety, dont miss these tips.

As for yourself: To get through this pandemic at your healthiest, dont miss these 35 Places Youre Most Likely to Catch COVID.

Read the original:
30 Things Stress Is Doing to Your Body - KYR News

Recommendation and review posted by Bethany Smith

President Donald Trump, who tested positive for COVID-19 on October 1, is now taking a steroid previously used in a clinical trial for hospitalized patients with the virus in the United Kingdom.

White House physician Sean Conley on October 4 updated reporters at the Walter Reed medical Center, where Trump is seeking medical care, on the presidents current condition. Following several conflicting and concerning reports from aides and doctors over the weekend, Conley offered a more optimistic approach on the 74-year-olds progress including a new prescription for Dexamethasone.

Since we last spoke, the president has continued to improve, Conley said.

Trump was taken to the Maryland military hospital on Friday after experiencing a high fever and receiving supplemental oxygen, the doctor explained. The presidents oxygen levels fell again on Saturday morning, requiring oxygen and a lung scan.

Conley said the scans showed some indications of damage, but assured it was nothing of a major clinical concern.

You can watch the full briefing here.

Trump may be discharged as early as tomorrow, another medical expert added during the briefing.

Heres what you need to know about Dexamethasone and its relation to COVID-19:

According to MayoClinic, Dexamethasone is prescribed to relieve inflamed areas of the body, including symptoms stemming from severe allergies, arthritis, asthma, adrenal problems, kidney problems, immune system disorders and skin conditions, among others.

It works on the immune system to help relieve swelling, redness, itching, and allergic reactions, the Clinic states.

The drug works by lowering the bodys natural defense response, WebMD added.

It is only available via a doctors prescription and comes in tablets, elixirs and solutions, the medical website continued.

GettyA healthcare worker tends to a patient in the Covid-19 Unit at United Memorial Medical Center in Houston, Texas.

The drug was used to treat hospitalized patients with the coronavirus in the United Kingdom during a national clinical trial called, RECOVERY, according to the World Health Organization.

The organization said the trial found the drug to be beneficial for critically ill patients, writing:

According to preliminary findings shared with WHO (and now available as a preprint), for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth.

The World Health Organization states on its website that Dexamethasone is fairly low-risk, presenting a favourable benefit-risk profile, particularly in patients with severe forms of pneumonia. Patients with non-severe pneumonia see lower benefits, on the other hand, it continued.

Non-threatening side effects include upset stomach, headache, dizziness, menstrual changes, trouble sleeping, increased appetite, or weight gain, WebMD states. If side effects persist or worse, a doctor should be notified promptly.

Long-term use, such as more than two weeks, could potentially cause more adverse reactions, WHO added, including glaucoma, cataract, fluid retention, hypertension, psychological effects, weight gain, or increased risk of infections and osteoporosis.

To reiterate: All these adverse events are not associated with short term use (with the exception of hyperglycaemia that can worsen diabetes), the organization says on its website.

GettyU.S. President Donald Trump wears a mask as he visits Walter Reed National Military Medical Center in Bethesda, Maryland.

Dean of the Brown University School of Public Health Ashish Jha said earlier this weekend that the drug could be a very clear signal that he has a more severe disease, according to The Los Angeles Times.

The Dean emphasized similar sentiments on October 4, expressing that Trumps long-term lung damage is still up in the air, the newspaper reported.

Trump was also half-way through his five-day course of the anti-viral drug Remdesivir, the Los Angeles Times reported.

Dexamethasone is generally available in most countries through several product manufacturers, WHO says.

One manufacturer has already been prequalified by WHO (Kern Pharma in Spain) while another is under assessment, the organization states on its website.

WHO claims the medication is also generally affordable,with a median price of $0.33 per 4mg/ml injection ampoules (range: US$0.13-$3.5), citing 2016 and 2019 surveys of health facilities in low- and middle-income countries.

READ NEXT: WATCH: Trump Mocks Biden During Debate, I Dont Wear Masks Like Him

Excerpt from:
Dexamethasone: 5 Fast Facts You Need to Know - Heavy.com

Recommendation and review posted by Bethany Smith

The first of six replacement steam engines arrives at Koeberg. Photo: EE Publishers

On the basis of a three-month shorter delivery time, the R5-billion steam generator replacement contract was finally awarded to French state-owned nuclear contractor, Areva, which, after running into financial difficulties, is now controlled by French national electricity utility, Electricite d France (EDF).

This followed an extended High Court, Appeal Court and Constitutional Court battle in South Africa, in which Westinghouse (ultimately unsuccessfully) tried to challenge the irregular contract award to Areva on the grounds that the claimed urgency of the life extension was deliberately contrived by Eskom in order to wrongfully award the contract to Areva.

At the time when Koeberg was built between 1976 and 1985, Framatome (the predecessor to Areva) manufactured the two 900 MW nuclear reactors and the six associated steam generators at Koeberg, using designs licensed from Westinghouse.

Both Eskom and Areva claimed that it was absolutely critical for the safe operation of the power plant, and for the security of electricity supply in South Africa, that the steam generators should be finally replaced during the so-called X23 outage at Koeberg in 2018.

This was cited by Eskom as the reason for awarding the contract to Areva, where an allegedly contrived three-month float in Arevas project plan was indicated as the deciding factor. This, despite Westinghouse having met all the technical and commercial requirements, with a lower contract price, and a guarantee to meet the 2018 completion date on pain of substantial penalties.

However, all has not gone well for Areva in executing the project.

Areva is said to have experienced serious manufacturing quality problems with the steam generator forgings in France. In view of the claimed time criticality of the project, to resolve these issues Eskom and Areva agreed that the uncompleted forgings would be air-freighted to China where an Areva partner would complete the manufacture.

Apparently, each of the six steam generator forgings required the hiring of a Russian Antonov freighter aircraft (six flights in total) to fly the forgings from France to China. However, according to an impeccable source, after taking a closer look at the forgings, Arevas Chinese partner decided to scrap them and start again from scratch.

One can only speculate as to why it was not considered more economical for Areva to fly engineers from the Chinese manufacturer to France to examine the steam generator forgings, as opposed to flying all six steam generators to China for the inspection, prior to them being scrapped in China.

A former senior nuclear executive at Eskom commented to this writer at the time that: This was the most expensive transport of scrap metal in the history of humankind.

Eskom confirmed to EE Business Intelligence last week that: The forgings did not meet the expected quality standards and could not be accepted, and therefore they were scrapped by the contractor at their own cost.

According to Eskom, the contractual delivery date of all six steam generators was February 2018, with the contractual completion date for the replacement of all six steam generators being the end of 2019.

However, with all the delays in the project, including restarting manufacture of the steam generators from scratch in China, delivery of the first three steam generators for Unit 1 at Koeberg is only starting now in September 2020, with those for Unit 2 only scheduled for delivery in the third quarter of 2021.

Regarding the actual replacement of the steam generators, Eskom now says that: Installation is aligned with the outages scheduled for 2021 and 2022 respectively for the two Koeberg reactor units (Unit 1 and Unit 2). No mention is now made by Eskom of the criticality for completion in 2018 cited by Eskom at the time as the reason for placing a more expensive contract with Areva.

While not answering specific questions on the cost overruns arising for the project, Eskom insists that: The estimated cost-to-completion for the project is within the original budget approved in 2014. Of course, this is not very helpful because the original budget approved in 2014 is not disclosed, and may have been significantly higher than the contract price.

However, it seems clear that Eskom has in fact paid a premium for the replacement by Areva of the steam generators at Koeberg on the basis of a claimed three-month shorter completion time, when in fact completion will be some three years longer.

Areva has previously not responded to queries regarding the scrapping of the generators.

DM/EE Publishers

Further reading:

[1] A very tender process: Eskoms Koeberg contract ruled unlawful, by Aimee Clarke and Chris Yelland, EE Publishers, 13 January 2016

[2] Westinghouse opposes Eskom, Areva appeal to Concourt, and lodges counter appeal, by Aimee Clarke and Chris Yelland, EE Publishers, 4 February 2020

[3] Eskom changing the goalposts and rules of the game at half-time?, by Aimee Clarke, EE Publishers, 26 May 2016

[4] Eskom and Westinghouse respond to article in Energize magazine and other publications, by Chris Yelland, EE Publishers, EE Publishers, 7 June 2016

[5] Eskom wins Concourt judgement, EE Publishers, 21 December 2016

More here:
Steam generators for Koeberg: the most expensive transport of scrap metal in the history of humankind - Daily Maverick

Recommendation and review posted by Bethany Smith